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ABSTRACT OF THE DISSERTATION
Allosteric Modulation of Metabotropic Glutamate Receptor 5 as a Treatment for Pain
by
Michael Christopher Montana
Doctor of Philosophy in Biology and Biomedical Sciences
Neurosciences
Washington University in St. Louis, 2012
Professor Robert Gereau, Chairperson
Metabotropic glutamate receptor 5 (mGlu5) has been suggested to play  a role in 
the development and maintenance of chronic pain. mGlu5 is expressed at synapses 
throughout the pain neuraxis where it  is believed to modulate the function of ion channels 
that underlie nociceptive transduction and transmission. Injections of mGlu5 agonists 
cause hypersensitivity or nocifensive behavior when administered peripherally, 
intrathecally, and centrally. In addition, pharmacological antagonism of mGlu5 has been 
suggested to be analgesic in a variety  of animal pain models. Unfortunately, the 
selectivity of antagonists used in these studies has been called into question, suggesting 
that at least some of the analgesic properties of putatively selective mGlu5 antagonists 
may be due to off-target  effects. Despite a wealth of data supporting the targeting of 
mGlu5 to treat pain, both antagonist selectivity  issues and the lack of an mGlu5 
antagonist approved for use in humans have hindered testing beyond the preclinical stage. 
To address this issue I assessed the pain behavior of mice with a genetic absence of 
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mGlu5. mGlu5 KO mice exhibit pain-like behaviors, however the duration and intensity 
of these behaviors are attenuated in multiple nociceptive tests, including spontaneous 
nociceptive behavior in the formalin test, and mechanical hypersensitivity  induced by 
Complete Freund’s Adjuvant. In addition, I assessed the analgesic properties of fenobam, 
[N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea], an 
anxiolytic recently  identified as a selective and potent non-competitive negative allosteric 
modulator of mGlu5, and previously  shown to be safe and effective in clinical trials of 
human anxiety. I found Fenobam to be analgesic in models of chemical nociception and 
inflammatory pain. Fenobam was also found to be without analgesic effect in mGlu5 KO 
mice, suggesting that its analgesic effect is mediated via mGlu5. Further assessment of 
both mGlu5 KO mice and the effects of fenobam suggested that mGlu5 may play a role 
in locomotion, weight gain, and appetite. Fenobam increases locomotive behavior, 
suggesting that antagonists of mGlu5 may exert  analgesic effects without causing dose-
limiting sedation. Overall these data suggest that mGlu5 is an important modulator of 
nociceptive plasticity, and that allosteric modulation of mGlu5 may represent a 
pharmacologic target for the treatment of pain.
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Chapter 1
Introduction to the Role of Metabotropic 
Glutamate Receptor 5 (mGlu5) in Pain
1
 The study of pain has occupied philosophers, physicians, and scientists 
throughout recorded history. Pain is a multifaceted sensory and emotional experience that 
is commonly associated with bodily  harm or injury.  The English word “pain” has roots in 
the Latin word poena or “punishment.” When considering physiological pain, 
punishment seems appropriate; physiological pain acts as a defense system that allows 
individuals to avoid or withdraw from noxious and dangerous stimuli. Following tissue 
damage, tenderness and hypersensitivity  at and around the site of injury encourage 
healing, by punishing an organism for overusing the affected area. Importantly, while 
physiological pain may be prolonged, it is reversible, and as healing occurs the necessity 
for pain to serve a protective role diminishes and the pain regresses. However, pain can 
outlast the injury and become chronic or pathologic. 
 The existence of chronic pain is a major clinical problem confronting patients and 
their physicians (National Center for Health Statistics, 2007). This document will focus 
on the role that metabotropic glutamate receptor 5 (mGlu5) plays in the development and 
maintenance of chronic pain and the possible clinical utility  that mGlu5 antagonists may 
have in alleviating that pain. In addition I will discuss the role that mGlu5 plays in 
physiological non-pain mechanisms to provide a context in which to address potential 
side effects of mGlu5 antagonists.
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Pain Terminology and Definitions
 Catalogued debate regarding the nature of pain dates to at least ancient Greece 
where Aristotle viewed pain as an emotion (Perl, 2007). An emotional aspect of pain 
remains in modern times, and the International Association for the Study  of Pain (IASP) 
defines pain as “an unpleasant sensory  and emotional experience associated with actual 
or potential tissue damage or described in terms of such damage” (Loeser and Treede, 
2008). While current views of pain are shaped by  a detailed understanding of anatomy 
and neurophysiology, many questions remain. Discoveries over the last several hundred 
years have shown that specific neuro-anatomical pathways are involved in the 
transmission of acute painful stimuli from the periphery to higher brain centers, and that 
these transmissions cross multiple synapses within both the spinal cord and the brain 
(Milan, 1999). We also know that pain perception can vary greatly depending on 
environment or context. For example, injury may result in previously non-painful stimuli 
being perceived as painful. However, the specific mechanisms that underlie these changes 
are not completely  understood. Plasticity  at multiple ascending synapses throughout the 
pain neuraxis likely plays a role in some of the profound changes that can occur in pain 
perception. In addition modulation of ascending afferents by descending neurons (e.g. 
pontospinal) within the spinal cord can also affect the perception of painful stimuli 
(Howorth et al., 2009). Individuals that suffer massive traumatic injuries may report  no 
pain at the time of the injury (Melzack and Wall, 1982). Unfortunately the reverse is also 
true, and both individuals with only minor injuries (Melzack and Wall, 2003, p. 276), and 
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those who have no discernible injury (Wolfe et al, 1990, 2010) may report  debilitating 
pain. A classic example is phantom pain, where painful sensations are perceived in a 
missing limb following amputation. The fact that pain can still be perceived in the 
missing limb is viewed as evidence that peripheral input is not required to experience 
pain. In addition, as the peripheral input is absent, changes elsewhere in the nervous 
system, either in the spinal cord or higher brain regions, must underlie this increased pain 
perception.
 Phantom limb pain is but one example of how plasticity within the nervous 
system may contribute to sensitization following injury  and the development of chronic 
pain. Nociception is the “neural process of encoding and processing noxious 
stimuli” (Loeser and Treede, 2008), and the perception of pain relies on the activation of 
neurons within the peripheral somatosensory system as well as the awareness of that 
stimulation due to activation of neurons in the spinal cord and brain. Altered pain 
perception following injury is thought to be due to increased responsiveness and reduced 
thresholds of neurons in the peripheral and central nervous system. Injuries that result in 
tissue damage often induce an inflammatory reaction that contributes to the sensitization 
of peripheral somatosensory neurons, reducing their firing threshold and increasing their 
responsiveness to stimuli within their receptive fields. This phenomenon is termed 
peripheral sensitization (Loeser and Treede, 2008). In addition, neurons within the central 
nervous system may become sensitized and exhibit increased responsiveness to input 
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from peripheral afferents, a phenomenon known as central sensitization (Loeser and 
Treede, 2008).
 Peripheral and central sensitization occur in nociceptive neurons, which are 
somatosensory neurons that encode potentially  or actually tissue damaging events, known 
as noxious stimuli (Loeser and Treede, 2008). Peripheral nociceptive neurons have nerve 
endings in the periphery that transduce and encode noxious stimuli. The perception of 
pain can arise from direct external stimulation and activation of nociceptors (nociceptive 
pain) or from damage or disease within the somatosensory system itself (neuropathic 
pain). It is important to note from the IASP definition of pain above the emotional 
component  pain is more than just sensation of noxious stimuli, it also has a strikingly 
negative affective component that can radically alter behavior and quality of life. 
Unpleasantness, distress, discomfort, and suffering can all be emotional descriptions of 
pain perception, and an integrated view of pain includes both an emotional and a sensory 
component. Thus factors that affect both the sensation of pain, such as the enhancement 
or blockade of peripheral nociceptive neural activity, and the emotional and behavioral 
responses, such as anxiety, stress, and awareness, may play important roles in pain 
perception. While acute pain is generally viewed as physiological and protective, 
prolonged pain that  outlasts the inciting stimulus can be detrimental and may be viewed 
as pathological. Pathophysiological changes within the nervous system can allow pain to 
be perceived in the absence of ongoing nociception. In addition, the perception of pain 
can be brought on by  a multitude of different inciting stimuli. Pain is a hallmark of many 
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disease processes and can by classified in multiple ways (Loeser and Treede, 2008; Woolf 
et al., 1998), including by location (e.g. abdominal pain), by mechanism (e.g. neuropathic 
pain), as a component of a disease (e.g. arthritis pain), by inciting factor (e.g. post-
operative pain), and by responsiveness to medication (e.g. indomethacin responsive 
headache), just to name a few.
 The significant impact pain has on both individuals and society has made it  a 
focus of major research efforts. Much of this research has been conducted in human 
subjects. However, the ethical and practical limitations of conducting pain research only 
in humans have resulted in the development of many laboratory  animal models for the 
study of pain. The complex nature of observing and interpreting animal behavior warrants 
a closer look at some of these models. 
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The Applicability of Pain Assessment in Rodents to Humans
 Much of the evidence and data presented below about the analgesic efficacy  of 
mGlu5 antagonists are derived from behavioral animal models of pain. It  is important to 
discuss some of the limitations of these animal models and how they are thought to apply 
to human pain conditions. As discussed above, human pain is a subjective experience that 
can be influenced by a multitude of factors, including level of awareness, surrounding 
environment, and stress. Animals possess many neuroanatomical pathways for 
transmitting information regarding peripheral nociception similar to those found in 
humans (Willis and Westlund, 1997). Additionally, as is true for humans, reported 
measurements of nociception in mice are susceptible to environmental and experimental 
state influences such as genetic background (Mogil et al., 1999), housing conditions, 
experimenter presence, diet, age, gender, (Mogil, 2009) and social cues (Langford, 2006). 
However, as elegantly stated by Bud Craig “A rat is not a monkey is not a 
human.” (Craig, 2009), and differences between humans and experimental laboratory 
animals exist with regard to both neuroanatomy, and, importantly, the ability  to report 
painful stimuli. Animals simply cannot verbalize when they are in pain, and surrogate 
measurements must be used such as withdrawal from stimuli, escape from noxious 
locations (e.g. extreme heat or cold), licking, shaking, or lifting of injured areas, as well 
as more complex behavioral readouts such as conditioned place preference (King et al., 
2009). Technically  we can never know whether an animal is in pain and thus 
hypersensitivity  and hyperalgesia (which may include decreased threshold to stimuli and 
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increased responses to suprathreshold responses), and spontaneous behavior are used as 
surrogates to infer pain. Of course it should be noted that no purely objective parameters 
such as specific biomarkers currently  exist for pain in humans either, and while human 
possess the benefit of language for communicating, pain is still a subjective experience in 
our species as well.
 While the inability to determine what experimental animals are subjectively 
experiencing marks a significant challenge to the direct applicability  of animal models to 
human pain conditions, there are a number of factors that contribute to the utility  of 
animal models of experimental pain, both now and in the foreseeable future. One of the 
foremost is the ability to use knockout animals to assess the role that  specific 
monogenetic influences play in pain behaviors. Knockout mice have been generated for a 
number of proteins involved in pain transduction and perception and have greatly 
contributed to our understanding of the specific roles these proteins play in pain 
transmission. For example, mice lacking the heat-gated cation channel TRPV1 show 
deficits in development of heat hypersensitivity following inflammation (Caterina et al., 
2000) and mice lacking mu-opioid receptors have profound impairments in their 
responses to the opioid agonist morphine (Matthes et al, 1996). While important 
considerations regarding compensation and genetic background exist when assessing 
genetically  modified animals (Larviere et al., 2001), genetically modified mice have 
proven indispensable in assaying the necessity for a specific protein in pain perception, or 
the target of action of an analgesic drug. In addition, the testing of animals is beneficial 
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for economic and ethical reasons : the effects of single genes or pharmacological 
treatments can be assessed in a battery of pain-related behavioral tests that would be cost-
prohibitive (due to sheer numbers) or unethical (e.g. controlled neuropathic pain injury 
models) to perform in humans.
 Specific pain related behavioral tests described in this thesis include the formalin 
test of spontaneous nocifensive behavior, complete Freund’s Adjuvant-induced 
mechanical and thermal hypersensitivity, and two models of neuropathic pain: the chronic 
constriction injury model, and the spared nerve ligation model. These models are 
discussed below.
Spontaneous Formalin-Induced Nocifensive Behavior: The formalin test is a model of 
acute to moderate duration pain. Spontaneous nocifensive behaviors (including licking, 
lifting, guarding, and flinching) are induced by  the injection of a dilute solution of 
formalin into the plantar surface of the mouse’s hindpaw (Dubuisson ad Dennis, 1977). 
Formalin concentrations used are generally  between 1% and 5% (of a 37% w/w solution 
of formaldehyde), dissolved in normal saline. Injection volumes for mice are usually 
limited to 10 microliters, due to volume constraints of the hindpaw. Immediately post 
injection a characteristic biphasic response is seen, the first  phase of which lasts for 
approximately 5 to 10 minutes, followed by a period of inactivity, and then a second 
phase of nociceptive behavior beginning around 15 to 20 minutes and lasting 
approximately another 15 to 20 minutes. Spontaneous nocifensive behaviors cease at 
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from between 45 to 60 minutes, however hypersensitivity  to mechanical and thermal 
stimuli may remain for days to weeks (Kolber et al, 2010; Wu et al., 2004). Spontaneous 
nocifensive behaviors can be scored by an observer and the responses of mice in different 
treatment groups or of different genotypes can be compared.
 The first phase of the formalin test is believed to be due to the direct activation of 
the ion channel TRPA1 (Macpherson et al., 2007; McNamara et al., 2007), although 
concentrations of formalin that are used for behavioral testing most likely  also cause 
generalized inflammation and no specific tissue damage. Initially  it was felt that  the 
second phase was solely due to ongoing inflammation and central sensitization within the 
spinal cord (McMahon and Koltzenburg, 2005, p.183), however continued discharge of 
A-delta and C-fibers that begin firing 15 minutes post injection suggest  that at least some 
of the second phase responses are due to ongoing peripheral nociceptor activity (Puig and 
Sorkin, 1996). Analgesics that  are known to modulate human pain, including opioids, 
NSAIDs, and the anti-convulsant gabapentin (Le Bars et al., 2001; Munro et al., 2007) 
are known to reduce spontaneous formalin behavior. The formalin test is felt to be one of 
the most predictive models of acute animal pain, in that drugs that are effective analgesics 
in humans are also largely  effective in reducing acute pain in animals (Le Bars et al., 
2001).
CFA-Induced Mechanical and Thermal Hypersensitivity: Complete Freund’s Adjuvant 
(CFA) is an emulsion of heat-killed Mycobacterium in paraffin oil. CFA causes an 
10
inflammatory response when injected into tissues due to its ability  to attract macrophages 
and other immune cells. This results in hypersensitivity  to both mechanical and thermal 
stimuli in animals (Alter et al., 2010; Ren, 1999) and in man (Gould, 2000). Thresholds 
to mechanical and thermal stimuli can be monitored in resting animals. Baseline 
measurements are made and then hypersensitivity is induced by subcutaneous injection of 
10 microliters of CFA into the dorsal hindpaw. The effects of both drugs and genotype on 
the development of and recovery from hypersensitivity can be assessed. Mechanical 
hypersensitivity  is commonly assessed on the hindpaw, but can also be assessed on the 
face or knee joint. Calibrated nylon monofilaments of increasing tensile strengths are 
applied to the plantar surface of the foot, and the bending force of the filament from 
which the mouse withdraws is recorded. Sensitivity to heat stimuli is measured in a 
similar manner, except the mouse is placed on a glass platform and a focused radiant light 
source is used to deliver a thermal stimuli to the hindpaw. The latency to withdraw from 
the heat source is used as the behavioral read out (Hargreaves et al., 1988).
Neuropathic Pain Models: The development of neuropathic pain results from direct 
damage or lesion to the somatosensory  nervous system (Loeser and Treede, 2008). 
Multiple models of neuropathic pain exist derive from different injuries to the nervous 
system. The most popular models try to mimic the partial nerve injury  that is usually  seen 
in neuropathic pain patients by inducing only a partial injury  instead of a complete lesion 
that would only  be seen following overwhelmingly severe injuries, such as amputation. 
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Two of the most common forms of inducing neuropathic pain are to perform a loose 
ligation around the sciatic nerve using chronic gut suture (Bennett  and Xie, 1988) and to 
selectively lesion two of the three primary distal branches of the sciatic nerve while 
leaving the third intact (Decosterd and Woolf, 2000). These models are respectively 
termed the chronic constriction injury model (CCI) and the spared nerve injury (SNI) 
model. Both models induce hypersensitivity  to thermal and mechanical stimuli that is 
responsive to known analgesics. The SNI model involves the transection of the tibial and 
common peroneal branches of the sciatic nerve, while leaving the sural nerve intact. This 
results in hypersensitivity developing on the lateral side of the hindpaw in the territory  of 
the sural nerve, which can be specifically probed for hypersensitivity. The SNI surgery 
itself is viewed as relatively easy to perform, however testing post injury requires careful 
attention to the area of the paw being probed as significant differences are found in 
responsiveness to stimuli applied to different nerve territories (e.g. sural vs. saphenous; 
Decosterd and Woolf, 2000; Zhao et al., 2004). The CCI model produces swelling and 
inflammation around the nerve and is intended to damage some but not all of the sciatic 
axons. It is inherently difficult to reproduce consistently and can result in variable 
responses to stimuli. However, testing of hypersensitivity is quite simple, because the 
entire paw of the organism is theoretically hypersensitized. Additional models of 
neuropathic pain also try to replicate diabetic peripheral neuropathy,drug-induced 
neuropathic pain, and direct spinal cord injury (Sandkuhler, 2009).
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 These animal models and others used throughout the pain research field represent 
powerful tools, especially in the assessment of new pharmacological treatments for 
painful conditions, while simultaneously  allowing for the assessment of potential 
undesirable effects that might endanger human patients and volunteers. It is also 
important to note that genetic and pharmacological manipulations of behaving animals 
may alter the behavioral readouts used to assess the analgesic effect of a given situation. 
For example, a drug that induces somnolence or causes motor impairment may also alter 
a behavioral readout surrogate of analgesia that requires intact motor function, 
independent of its analgesic effect (e.g. paw withdrawal). For this reason in addition to 
the pain related behavioral tasks presented below I have also assessed locomotion, motor 
coordination, and other potential effects, which if altered, could confound interpretations 
of pain-related behavior. Ultimately animal testing is an important and useful component 
of pain research, so long as the obvious caveats are addressed. Many analgesics currently 
used in humans have been shown to be efficacious in animal models of pain (Mogil, 
2009), and molecules and techniques tested in animals have been successfully applied to 
the treatment of human pain conditions. Still no panacea for chronic pain exists. While 
current treatment regimens are very effective in treating some types of pain (e.g. acute 
post-operative pain), the effective treatment of chronic pain is a largely unmet goal. Also 
as discussed below, many highly effective analgesics suffer from poor therapeutic index. 
The need for additional treatments is paramount and the use of animal pain models will 
be critical to future endeavors. 
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Examples of Currently Available Pharmacological Therapeutics and Their Limitations
 Current treatments for pain rely  on a variety  of pharmacological therapeutics, 
surgical interventions, physical therapy, psychological/psychiatric approaches, and their 
use in combination. Present pharmacological therapies include several different classes of 
medication such as anti-pyretic agents, nerve-blockers, opioids, and anti-epileptics. While 
many of these agents are highly effective in controlling pain, they all have specific 
settings in which they are and are not useful, as well as dose-limiting side effects. 
Additional drugs in the pharmacological armamentarium may address some of the 
limitations of currently available therapeutics and bridge current gaps in coverage. 
 Pain relievers derived from natural products have long been used by human 
civilizations. Two of the most prominent examples are willow bark preparations that 
contain salicylic acid (from which the antipyretic analgesic aspirin can be synthesized) 
and the poppy seed extract opium (which contains the opioid narcotic morphine). Despite 
centuries of use, the precise mechanisms of action through which these drugs exert their 
analgesic effects have only come to light in the last half century  (Vane, 1971; Pert, 1973). 
While both salicylate derivatives and opiates are outstanding analgesics, they are not 
effective in the treatment of all types of pain and have undesirable side effect profiles that 
can result in significant morbidity when used long term. The discovery of both new 
analgesics and the analgesic properties of drugs originally developed for different 
purposes has generated major advances in the ability  to treat chronic pain. Here I will 
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discuss the clinical utility  and dose limiting effects of a few classes of analgesic 
medications.
Non-steroidal Anti-inflammatory  Drugs (NSAIDs) and Antipyretics: Arachidonic acid 
(AA) is synthesized from cell membrane phospholipids in response to a variety  of 
stimuli, including inflammation (Rao and Knaus, 2008). The enzyme cyclooxygenase 
(COX) catalyzes the conversion of AA to prostaglandin G2 (PGG2) and subsequent 
intracellular reactions result in the production of several additional prostaglandins 
including the pyretic prostaglandin PGE2. Several prostaglandins are pro-algesic and can 
sensitize primary afferent nociceptive neurons (Melzack and Wall, 2003, p. 345; Lopshire 
and Nicol, 1997) and act synergistically  with other inflammatory mediators such as 
bradykinin (Taiwo and Levine, 1988). The analgesic effects of NSAIDs, including 
salicylate derivatives such as aspirin, are largely  attributed to their ability to act as COX 
inhibitors and thus decrease the synthesis of prostaglandins (Vane, 1971). NSAIDs have 
clinical utility in the treatment of pain, especially in conditions associated with 
inflammation, such as rheumatoid arthritis. However, in rheumatoid arthritis, NSAIDs 
only provide symptomatic relief and do not alter disease progression (Melzack and Wall, 
2003, p. 45). NSAIDs are also useful in the treatment of migraine headache, post-
operative pain, and cancer pain (Melzack and Wall, 2003, p. 347). Unfortunately, 
nonselective COX inhibitors such as aspirin can be toxic to the GI tract and kidney. 
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 Aniline derivatives, such as acetaminophen, are antipyretic and analgesic non-
NSAIDs, and have fewer side effects than salicylates when dosing guidelines are 
maintained (Melzack and Wall, 2003, p. 348). Unfortunately acetaminophen overdose is 
also the most common cause of acute liver failure (Ostapowicz et al., 2002), which can 
result in fatality  or require liver transplant. In addition, acetaminophen lacks peripheral 
anti-inflammatory effects, and there are some inflammatory pain conditions, such as 
rheumatoid arthritis, in which patients prefer NSAIDs over acetaminophen based on 
effectiveness (Wolfe et al., 2000).  Thus NSAIDs and antipyretics represent the classical 
issues of balancing clinical effectiveness, disease appropriateness, and safety  common in 
other classes of medication.
Opioids: Opioids inhibit the perception of pain by activating endogenous analgesic 
systems in the spinal cord and brain, which in turn modulate ascending pain transmission 
along the pain neuraxis (Fields, 2004). Multiple opioid receptor subtypes exist  within the 
nervous system, however, the primary  analgesic actions of most opioids in clinical use 
result from activation of the µ-opioid receptor, which is expressed both pre- and post-
synaptically throughout the endogenous pain-modulating circuit. Morphine is the 
prototypical µ-opioid receptor agonist, and a powerful analgesic (Melzack and Wall, 
2003, p. 379). However, concomitant side effects, including nausea, vomiting, narcosis, 
constipation, respiratory  depression, opiate-induced itch, and tolerance (Melzack and 
Wall, 2003, p. 389-392) require a careful assessment of the risk / benefit ratio when 
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administering opioids. Additionally, patient perception that addiction is likely (Melzack 
and Wall, 2003, p. 385-86) may decrease patient  enthusiasm for initiating opioid therapy. 
Regardless of these issues, opioids are a mainstay of cancer and peri-operative pain 
management. The combination of opioids with adjuvant analgesics (e.g. NSAIDs and 
anticonvulsants) can also be used to decrease the dose of opioid required to achieve 
analgesia, and thus decrease the incidence of side-effects. The discovery  of new drugs 
that could act as a opioid adjuvants would be beneficial to the treatment of pain.
Anticonvulsants: Anticonvulsants developed to decrease neuronal firing rates in epilepsy 
have been found to possess clinical utility  in the treatment of neuropathic pain, possibly 
through the modulation of ion channels required for action potential generation (Tremont-
Lukats et al., 2000). Gabapentin is a prime example of the successful use of 
anticonvulsants as analgesics. Originally developed as an oral anticonvulsant (Bruni et 
al., 1991; UK Gabapentin Study Group, 1990; US Gabapentin Study Group No. 5, 1993) 
it has been shown to be effective compared to placebo in the treatment of post-herpetic 
neuralgia (Rowbotham et al., 1998) and was approved by  the FDA for the management of 
that condition. The precise mechanism of action by which gabapentin exerts its analgesic 
actions is unknown, however it  has been suggested that it mediates some of its analgesic 
effects via binding to α-2-δ calcium channels (Gee et al., 1998) and inhibiting 
neurotransmitter release and ectopic discharge (Pan et  al., 1999; Taylor et al., 1998). 
Gabapentin has also been shown to be analgesic in multiple animal pain models (refs). 
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While generally well tolerated gabapentin administration is not without adverse events, 
and gabapentin may cause dizziness and somnolence, as well as rare incidents of life-
threatening angioedema and suicidal ideation (Pfizer, 2010). Still the use of gabapentin as 
an analgesic represents a prominent success story in the use of drugs originally  developed 
for other purposes as analgesics. 
Future Directions in Analgesia Development: Rational design of entirely  new classes of 
analgesics has been based on recent discoveries in signal transduction of nociceptive 
stimuli. For example, the algogenic chili pepper extract capsaicin was discovered to 
induce pain by selectively activating the heat-sensitive cation channel TRPV1 on 
peripheral nociceptors (Caterina et  al., 1997). Unfortunately, some setbacks have 
occurred, as TRPV1 antagonists have also been shown to induce significant  hyperthermia 
(Gavva et al., 2008). TRPV1 expression in central brain regions, including the 
hippocampus, and the reported role for TRPV1 in mediating long term depression (LTD) 
(Gibson et  al., 2008), may also represent hurdles to the development of antagonists as 
analgesics. It is critical to develop new classes of analgesics based on an understanding of 
their roles in pain processing and plasticity. Glutamate receptor signaling is a prime target 
for this type of drug development, as its roles in pain processing and plasticity have been 
extensively characterized during the last decade.
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Metabotropic Glutamate Receptor 5 (mGlu5) as a mediator of Peripheral and Central 
Sensitization and a Potential Therapeutic Target for the Treatment of Pain
Metabotropic Glutamate Receptor Classes and Signaling Cascades: Glutamate is the 
primary excitatory neurotransmitter in the vertebrate nervous system. It mediates its 
effects via activation of two main classes of receptors: ligand-gated ion channels known 
as ionotropic receptors and G-protein coupled metabotropic receptors. Metabotropic 
glutamate receptors (mGluRs) belong to the Class C family  of G-protein coupled 
receptors (GPCRs) whose structure includes a large venus-flytrap-shaped extracellular N-
terminal domain where endogenous ligands, synthetic orthosteric agonists, and 
competitive antagonists bind. Like all GPCRs, mGluRs possess a seven transmembrane 
domain region that is responsible for coupling to G-proteins (Bhave et al., 2003). Within 
the mGluR family eight distinct receptor subtypes have been identified. These receptors 
are divided into three major groups based on sequence homology, signal transduction 
mechanisms, and pharmacological profiles (Conn, 2003). In heterologous systems group 
I mGluRs (mGlu1 and 5) couple to the stimulatory G-protein Gq and subsequently to the 
activation of phospholipase C (PLC) and the release of intracellular calcium. Group II 
(mGlu2 and 3) and III (mGlu4, 6, 7, and 8) mGluRs couple to the inhibitory G-protein 
Gi/o and subsequently inhibit adeylyl cyclase. Group II and III mGluRs also couple to the 
activation of G-protein coupled inwardly rectifying potassium channels (Knoflach and 
Kemp, 1998; Watanabe and Nakanishi, 2003) and the inhibition of voltage gated calcium 
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channels (Conn and Pin, 1997). mGluRs are expressed both pre- and post-synaptically: 
however group I mGluRs are primarily localized to the postsynaptic density where their 
activation results in an increase in neuronal excitability, while group II and III mGluRs 
are primarily  localized to presynaptic terminals and function as auto-receptors to regulate 
neurotransmitter release (Testa et al., 1998; Lovinger and McCool, 1995).
Distribution of mGluRs Throughout the Nervous System: Following the initial discovery 
of mGluRs in 1991 and the subsequent discovery of a total of eight  members of the 
mGluR family, (Masu et al., 1991), mGluRs have been shown to be expressed throughout 
the nervous system. Importantly mGluRs are expressed at all levels of the pain neuraxis, 
including the spinal cord and periphery  (Varney and Gereau, 2002). mGluRs are 
expressed extensively  throughout the brain, with the notable exception of mGlu6, which 
is expressed exclusively  in the retina. (Ferraguti and Shigemoto, 2006) mGlu1 exhibits 
robust expression in the cerebellar cortex, substantia nigra, and hippocampus as well as 
slightly lower expression in neocortex, amygdala, and striatum (Martin et al., 1992). 
mGlu5 is found throughout the cerebral cortex, hippocampus, striatum, and amygdala. Of 
specific interest to pain processing is the expression of mGlu3, 5, and 7 (Varney  and 
Gereau, 2002) within the periaqueductal grey (PAG). Ascending fibers carrying pain and 
temperature information from the spinal cord via the spinomesencephalic tract synapse 
within the PAG. In addition, the PAG plays a major role in the descending modulation of 
pain. Another brain region of particular relevance to pain processing is the amygdala. 
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Pain is associated with negative emotional responses and in humans the amygdala is an 
important center for the processing of emotional information. The amygdala is activated 
during pain in both humans and rodents (Schneider et al., 2001; Ji and Neugebauer, 2008; 
Kolber, et al., 2010) and activation of group I, II, and III mGluRs within the amygdala (Li 
and Neugebauer, 2004 & 2006; Kolber et al., 2010) can modulate nociceptive processing. 
Finally, members of all groups are found in the thalamus, with notable expression of 
mGlu1, 4, and 7 in nuclei that receive sensory and pain inputs (VPM  and/or VPL) 
(Lorenco Neto et al., 2000).
 Expression of all Group I and II mGluRs as well as mGlu4 and 7 has been noted in 
the spinal cord (Karim et al., 2001; Jia et  al. 1999; Chiechio et  al., 2002; Varney and 
Gereau, 2002). Expression levels for mGlu2, 3, and 5 are particularly high in the spinal 
cord dorsal horn, where first order peripheral sensory  neurons carrying nociceptive 
information synapse onto second order neurons, including ascending projection neurons. 
In addition, members of all mGluR groups are expressed in the peripheral nervous system 
within the cell bodies of the dorsal root ganglia in rats (Carlton and Hargett, 2007), and 
mGlu5 has been identified by immunohistochemistry  in human DRGs (Valerio et al., 
1997). Over the past two decades a growing body  of evidence has contributed to the 
hypothesis that metabotropic glutamate receptors, and particular mGlu5, are involved in 
both the induction and maintenance of pain.
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The Role of mGlu5 in Pain Plasticity: The first suggestion that mGluRs may play  a role 
in nociceptive transmission came in 1994 from two separate groups. Young et  al. (1994) 
demonstrated that the putatively  competitive mGluR antagonist L-AP3 inhibited the 
excitation of spinal cord dorsal horn neurons induced by the cutaneous application of 
mustard oil. This work was extended to suggest that  the sustained nociception evoked by 
repeated cutaneous application of mustard oil could also be inhibited by blocking the 
activation of mGluR mediated intracellular signaling pathways such as PLC (Young et 
al., 1995). At the same time, Neugebauer et al. demonstrated that L-AP3 reduced the 
responses of hyperexcitable spinal cord neurons following acute inflammation in the knee 
joint (Neugebauer et al., 1994). Interestingly, L-AP3 had no effect on either noxious or 
innocuous pressures applied to the normal knee joint, suggesting that activation of group 
I mGluRs was selective for inflammation-evoked hypersensitivity  and not necessary for 
the responses elicited under normal conditions. Unfortunately, the non-selective nature of 
L-AP3 and other early pharmacological tools used to assess the mGluRs (Schoepp  et al., 
1999) make the interpretation of some of these early experiments difficult. However 
additional studies using more selective pharmacological agents suggest  that activation of 
group I mGluRs in both the periphery and the spinal cord is indeed pronociceptive 
(Neugebauer et al., 1999; Dolan and Nolan, 2000; Bhave et al., 2001; Karim et al., 2001). 
 A principal mechanism by which mGlu5 promotes hypersensitivity  is through the 
modulation of nociceptive transduction channels in peripheral terminals of primary 
afferent neurons. For example, peripheral injection of the group I mGluR agonist 
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R,S-3,5-dihydroxyphenylglycine (DHPG) results in thermal hypersensitivity in mice 
(Bhave et al., 2001; Hu et al, 2002). This is believed to result from the activation of a 
complicated signaling pathway where group I mGluR activation couples to PLC 
activation, and results in the generation of diacylglcerol, which is metabolized into the 
inflammatory mediator arachidonic acid. Further metabolism of arachidonic acid results 
in the production of prostaglandins via the cyclooxygenase (COX) pathway and the 
eventual sensitization of the capsaicin receptor TRPV1 (Hu et al., 2002), which is 
required for the molecular changes underlying inflammation-evoked thermal 
hypersensitivity  (Caterina et  al., 2000; Davis et al., 2000). In sensory neurons, DHPG-
induced enhancement of calcium responses following application of the TRPV1 agonist 
capsaicin has been primarily  attributed to mGlu5 (Hu et al., 2002). mGlu5-mediated 
potentiation of these capsaicin-evoked responses is attenuated by  both the PLC inhibitor 
U73122 and the DAG-lipase inhibitor RHC-8026719, suggesting a prominent role for 
mGlu5- stimulated, PLC-activated PIP2 signaling pathways in thermal hyperalgesia. 
Additionally, the potentiation of these capsaicin-evoked responses is also blocked by  the 
COX inhibitors indomethacin and ibuprofen, and the prostanoid receptor antagonist 
SC-51089. Results from in vivo studies demonstrate that  inhibitors of mGlu5 (MPEP) and 
COX (indomethacin, aspirin) block DHPG-induced thermal hyperalgesia (Hu et al., 
2002). Taken together, these data suggest that mGlu5-stimulated PLC activation in 
sensory neurons – and the subsequent activation of downstream prostaglandin 
inflammatory mediators – promotes thermal hyperalgesia via modulation of TRPV1.
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 A prominent role for mGlu5 in the development of central sensitization has also 
been suggested. Modulation of ion channels within the spinal cord may contribute some 
of the molecular changes that  underlie central sensitization (Ji et al., 2003). For example, 
decreased potassium channel function or effectiveness could manifest in increased 
neuronal excitability. A specific ion channel that is expressed in dorsal horn neurons and 
is known to modulate neuronal excitability  is KV4.2, which contributes to the fast 
transient outward potassium current (IA) (Hu et al., 2003). Genetic deletion of KV4.2 
results in increased excitability  of dorsal horn neurons and increased sensitivity  at 
baseline to mechanical stimuli. Interestingly  however, KV4.2 knockout mice do not 
demonstrate increased hypersensitivity following activation of extracellular signal-
regulated kinase (ERK) (Hu et al., 2006), a known modulator of pain hypersensitivity  (Ji 
et al., 1999). ERK is an integrator of intracellular signaling cascades that are initiated in 
the spinal cord following painful stimuli, and ERK activation contributes to central 
sensitization (Ji et al., 2009). The activation of mGlu5 in the dorsal horn of the spinal 
cord functionally couples to the activation of the ERK (Karim et al., 2001) and the 
subsequent phosphorylation of Kv4.2 (Hu et al., 2007), which results in increased 
excitability of dorsal horn neurons. This mGluR5-ERK-Kv4.2 regulation of dorsal horn 
neuronal excitability is believed to represent a cellular underpinning of inflammation-
induced central sensitization in the spinal cord. Thus, both peripheral and central 
activation of mGlu5 has been demonstrated to modulate pain plasticity. 
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Allosteric Modulation of mGlu5
 Exciting advances in recent years have yielded numerous small molecule 
allosteric modulators of mGluRs that bind within the transmembrane domain at a 
topographically distinct location from the glutamate binding site. Pharmacological 
dissection that  provides much of the evidence of the role mGlu5 plays in pain plasticity 
has been largely  conducted using these drugs. Allosteric modulators mediate their effects 
by exhibiting one or more of three pharmacological properties. First, allosteric 
modulators can exhibit affinity modulation and alter the affinity of the receptor for its 
endogenous ligand. Second, efficacy  modulation may occur such that the binding of an 
allosteric modulator alters the strength of the downstream signaling cascades induced by 
the orthosteric ligand. Finally some allosteric modulators may have positive or negative 
intrinsic activity on the receptor itself such that they function as agonists or inverse 
agonists regardless of the binding of the orthosteric ligand. With respect to mGlu5, 
positive allosteric modulators (PAMs) increase, and negative allosteric modulators 
(NAMs) decrease, the response of the receptor to glutamate. (Conn et al., 2009)
 The ligand binding site often has high sequence homology across members of a 
family of GPCRs, making development of selective agonists or antagonists against a 
specific receptor subtype difficult. However, modern high-throughput screening for 
receptor activity modifiers allows for the identification of compounds that bind elsewhere 
in the receptor, and has allowed for the development of allosteric modulators that have 
improved receptor subtype specificity  when compared to compounds that bind at the 
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endogenous ligand binding site (Conn et al., 2009). Additionally, some allosteric 
modulators do not possess intrinsic activity at the receptor, and only exert an effect when 
an orthosteric ligand is bound. These molecules would theoretically exhibit activity-
dependence, only modulating the system when and where it is activated under 
physiological conditions. For these reasons, allosteric modulators represent attractive 
candidates for development as pharmacological agents that target mGluRs.
 The development of the non-competitive mGlu5 antagonist MPEP (Gasparini et al., 
1999) addressed a need for a selective pharmacological tool to probe the role of mGlu5 in 
chronic pain. While the related compound MTEP (Cosford et al., 2003) is generally 
thought to be more potent and selective (Lea and Faden, 2006) much of the mGlu5 
research over the past decade has utilized MPEP. Systemic MPEP administration reverses 
mechanical hyperalgesia induced by  the inflammatory agents Complete Freund’s 
Adjuvant (CFA) and carrageenan, and oral administration was found to have improved 
gastrointestinal safety over the NSAIDs indomethacin and diclofenac (Walker et al., 
2001a). In addition peripherally administered MPEP was found to significantly reduce 
CFA induced inflammatory hyperalgesia (Walker et al., 2001b) suggesting a role for 
peripherally expressed mGlu5 in pain. Bhave et al. (2001) further expanded upon this 
work by demonstrating the expression of group I mGluRs on the peripheral terminals of 
nociceptors, and showing that peripheral injection of the group I mGluR agonist DHPG 
induces thermal hypersensitivity in mice. This DHPG induced hypersensitivity  was 
blocked by peripheral injections of MPEP. Furthermore, peripheral injections of MPEP 
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were able to prevent and reduce spontaneous behavior following intraplantar formalin 
injection (Bhave et al., 2001). 
 Neuropathic pain has also been suggested to be susceptible to modulation by 
mGlu5 antagonists. Intrathecal injection of the mGlu5 antagonist SIB-1757 is able to 
reduce mechanical allodynia following spinal nerve ligation (SNL) as well as reverse 
SNL-induced thermal hyperalgesia (Dogrul et al. , 2000). In addition, 
intracerebroventricular (i.c.v.) injections of MPEP dose-dependently inhibit cold 
hypersensitivity  following chronic constriction injury (CCI) of the sciatic nerve in rats 
(Urban et al., 2003). Brain receptor occupancy studies following systemic MPEP 
injections suggested that >90% receptor occupancy is required for effective analgesia. Of 
note, neither intrathecal nor intraplantar injections of MPEP were found to be effective in 
reducing cold hypersensitivity  post-CCI (Urban et al, 2003), however in both cases only 
one dose of MPEP was tested and no dose-response measurements were performed. 
Furthermore, a separate study  found that systemic MPEP injections were able to reduce 
mechanical hypersensitivity  induced by multiple neuropathic pain models (Zhu et al., 
2004), indicating that multiple sensory modalities may be susceptible to modulation by 
mGlu5 antagonists following neuropathic injury. 
 Taken as a whole, the literature suggests that  MPEP is analgesic in multiple 
nociceptive modalities, and may exert its effects at multiple sites within the pain neuraxis 
(Table 1). This would seem to provide strong evidence that  mGlu5 plays a prominent role 
in pain plasticity. However, suggestions that MPEP may  act both as a weak NMDA 
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receptor antagonist with micromolar potency (O’Leary et al., 2000; Movsesyan et al., 
2001; Lea and Faden, 2006), and as an inhibitor of the norepinephrine transporter
(Heidbreder et al., 2003), have tempered the enthusiasm that it is functioning exclusively 
via mGlu5. The continued quest for highly  selective mGlu5 antagonists was greatly 
furthered in 2005 by researchers at Hoffman-LaRoche in Switzerland (Porter et al., 
2005). They demonstrated that  the non-benzodiazepine anxiolytic fenobam is a potent 
and selective negative allosteric modulator of mGlu5 with a chemical structure distinct 
from MPEP. This finding was especially exciting as fenobam had previously been tested 
in clinical trials in the 1980s where it was found to be an effective anxiolytic with a good 
safety  profile (Pecknold et al., 1980, 1982; Lapierre and Oyewumi, 1982). However, due 
to potential side effects and (during the 80s) an unknown mechanism of action, fenobam 
was never pursued as a commercial product.
 Interestingly, in addition to its analgesic properties, the mGlu5 antagonist  MPEP 
has also been demonstrated to have anxiolytic effects (Varty  et al., 2005; Ballard et al., 
2005). Furthermore MPEP (Yan et al., 2005), and mGlu5 antagonists in general (Dolen et 
al., 2007), have been suggested as potential therapeutics for the treatment of Fragile X 
syndrome (FXS). The hypothesis that fenobam would function as a clinical therapeutic 
for FXS in humans was recently tested (Berry-Kravis et al., 2009). Fenobam 
demonstrated some mild beneficial effects and was found to be without significant 
adverse effects in both healthy volunteers and FXS patients . Prior to the work presented 
in this thesis, the efficacy of fenobam in the treatment of pain was untested. 
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Summary of Findings: mGlu5 as a Target for the Treatment of Pain
 Both peripheral and central activation of mGlu5 has been suggested to modulate 
pain plasticity, and pharmacological antagonism of mGlu5 at peripheral and central sites 
has been suggested to be analgesic. It is therefore conceivable that pharmacological 
therapeutics designed to modulate mGlu5 would represent viable analgesics in humans. 
However, as discussed above, the questionable selectivity of MPEP has prevented the 
unambiguous determination of the role that mGlu5 plays in pain. 
 Direct testing of the necessity  of mGlu5 in pain plasticity using genetically 
modified animals has not been previously conducted. One of the primary  goals of this 
thesis was to assess the pain related behaviors of a colony of mGlu5 KO mice as 
compared to their WT littermates. This was intended to test directly the assumption that 
mGlu5 is required for the full expression of pain-related behaviors, while simultaneously 
avoiding the issue of antagonist selectivity. In Chapter 2 I present evidence that mGlu5 
KO mice have deficits in several nociceptive behaviors, suggesting that mGlu5 is 
required for the full expression of pain. 
 All previous work involving the study of mGlu5 in pain has been performed using 
animal models and other pre-clinical experiments. Future endeavors aimed at the 
development of mGlu5 antagonists as analgesics would be aided by an antagonist  that has 
been shown to be clinically viable and safe in human subjects. Therefore, one of the goals 
of this thesis was to test the hypothesis that fenobam is analgesic in rodents, thus 
providing the necessary  preclinical evidence to proceed with future clinical trials in 
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humans. Results from studies suggesting that fenobam is analgesic in rodents are 
presented in Chapter 3. Additionally, the demonstration that mGlu5 antagonists are 
devoid of analgesic efficacy in mGlu5 KO mice would provide compelling evidence that 
they  are mediating their analgesic effects by inhibiting mGlu5. Therefore another goal of 
this thesis was to assess the analgesic effects of both fenobam and MPEP in mGlu5 KO 
mice. Results from these experiments are also presented in Chapter 3.
 Finally, future clinical development of mGlu5 antagonists as analgesics will not 
only depend on analgesic efficacy, but also a lack of debilitating or dose-limiting side 
effects. An assessment of the locomotor and motor-coordination related behaviors of 
mGlu5 KO mice as well as the effects of fenobam on these behaviors is presented in 
Chapter 4. While mGlu5 KO mice seem to have altered locomotor behavior that is also 
induced by fenobam in WT animals, it is possible that these effects may not impede the 
development of analgesics as mGlu5 antagonists. One potential way to avoid centrally-
mediated side effects would be to use peripherally restricted mGlu5 antagonists. As 
mentioned above, mGlu5 is expressed throughout the pain neuraxis and both peripheral 
and central receptors have been proposed to play  a role in pain-related behaviors. Thus 
peripheral receptors could theoretically be selectively or preferentially targeted over 
central receptors to induce analgesia without inducing centrally  mediated side effects. 
Unfortunately neither the precise role of peripheral mGlu5 in pain, nor the existence of 
any peripherally restricted mGlu5 antagonists needed to test this hypothesis, are presently 
known. In order to assess the necessity  of peripheral mGlu5 in pain I sought to test the 
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pain related behaviors of a colony of mice in which mGlu5 has been selectively deleted 
only from peripheral nociceptors. In Chapter 5 I present findings that suggest that 
peripherally restricted mGlu5 KO mice do not have alterations in their pain related 
behaviors. While this decreases enthusiasm for the development of peripherally restricted 
mGlu5 antagonists as analgesics, taken together the bulk of the data presented in this 
thesis suggest that antagonism of mGlu5 may represent a viable therapeutic option for the 
treatment of pain in humans. 
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Chapter 2
The Pain Related Behaviors 
of mGlu5 KO Mice
33
INTRODUCTION
 As discussed above, mGluRs modulate neurotransmission by coupling to 
intracellular signaling cascades (Niswender and Conn, 2010). In addition to playing 
important roles in synaptic plasticity, learning and memory, anxiety, and other 
neurological disorders, mGlu5 is expressed at synapses throughout the pain neuraxis 
(Varney and Gereau, 2002) where it has been shown to play a role in the modulation of 
multiple nociceptive modalities. mGlu5 agonists induce hypersensitivity when 
administered both peripherally and centrally (Bhave et al., 2001, Kolber et al., 2010), and 
intrathecal injections cause spontaneous nociceptive behaviors in mice (Karim et al., 
2001). Conversely mGlu5 antagonists have analgesic effects when delivered systemically, 
(Zhu et al., 2004; Walker et al., 2001a) intrathecally, (Karim et al., 2001), and 
peripherally (Bhave et al., 2001; Walker et al., 2001b; Zhu et al., 2005). However, there is 
some controversy regarding the selectivity of these antagonists, and suggestions have 
been made that their analgesic effects are not mediated entirely by mGlu5 (O’Leary  et al., 
2000; Movsesyan et al., 2001; Lea and Faden, 2006). The issue of antagonist selectivity 
will be directly addressed in chapter 3. Here I sought to circumvent the issue of 
antagonist selectivity by using a genetic strategy to test the role of mGlu5 in pain. In this 
section I present data from mouse pain models used to assess the nociceptive behaviors of 
mGlu5 KO mice (Jia et al., 1998) and their WT littermates. These mice were generated in 
the lab of John Roder at the Samuel Lunenfeld Research Institute in Toronto, Ontario. A 
0.4-kb fragment containing a portion of exon 1 and intron 1 was deleted and replaced 
with a 1.8-kb fragment containing a PGK-neomycin cassette. 
34
	
 I used a battery of inflammatory and neuropathic pain models, including DHPG- 
and Complete Freund’s Adjuvant (CFA)-induced hypersensitivity, spontaneous formalin 
behavior, and both chronic constriction injury- and spared nerve injury-induced 
hypersensitivity. I have found that mGlu5 deficient mice have reduced responses in 
multiple pain behavioral models. 
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METHODS
Animals: Experiments were performed in accordance with the guidelines of the National 
Institutes of Health and were approved by  the Animal Care and Use Committee of 
Washington University School of Medicine. mGlu5 KO mice (6 to 8 weeks old) were 
bred inhouse on a C57BL/6 background and compared to WT littermates (Jia et al., 
1998). Blinding to genotype was accomplished by using coded ear tag identification 
numbers and only breaking the code at the end of the experiment. Unless otherwise 
specified only male mice were tested. All mice were group housed on a 12/12-light/dark 
schedule with lights on at 0600 CST and ad libitum access to food and water.
PCR Genotyping: Genotyping of mice bred inhouse was performed using standard PCR 
techniques with primers targeted to exon 1 of the mGlu5 locus. Three primers were used, 
a forward oriented common primer upstream of the deleted segment, and two reverse 
primers  a WT primer within the deleted segment, and a KO primer within the 
neomycin cassette.
Primers:
1) Common Primer  oIMR1034  CAC ATG CCA GGT GAC ATC AT
2) Wild Type Primer  oIMR1035  CCA TGC TGG TTG CAG AGT AA
3) Knock Out Primer  oIMR2060  CAC GAG ACT AGT GAG ACG TG
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Genotyping Reaction Master Mix (per reaction):
1) MilliQ Water: 8.4 µl
2) GoTaqFlexi (Promega) 5x Buffer: 4 µl
3) MgCl2 (25 mM): 2 µl
4) WT Primer: 1 µl
5) Common Primer: 2 µl
6) KO Primer: 1 µl
7) dNTPs (10 mM): 0.4 µl
8) GoTaq (Promega): 0.2 µl
9) Extracted Tail DNA: 1 µl
PCR Protocol:
Cycle 1 (1x):  Step 1: 94oC for 3 minutes 
Cycle 2 (35x): Step 1: 94oC for 30 seconds
  Step 2: 62oC for 45 seconds
  Step 3: 72oC for 45 seconds
Cycle 3 (1x): Step 1: 72oC for 2 minutes
  Hold at 4oC until agarose gel separation
Gel Separation: PCR product separation on a 1.5% agarose gel yields 2 bands, a KO 
band at ~650 bp, and a WT band at ~440 bp. Heterozygous animals have both bands. 
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Immunohistochemistry: WT and mGlu5 KO littermate mice were deeply anesthetized 
with a 100 µl injection of ketamine, acepromizine, and xylazine (KAX) (42.86 mg/ml, 
8.57 mg/ml, and 1.43 mg/ml KAX respectively), then perfused transcardially with 0.5% 
procaine in PBS (37oC), followed by  20 ml of ice-cold 4% paraformaldehyde dissolved in 
PBS. The brain and spinal cord were dissected immediately  and cryoprotected overnight 
in 30% sucrose dissolved in PBS. Tissue samples were mounted in Sakura Tissue-Tek 
O.C.T. Compound (VWR) and frozen on dry-ice and then stored at  -80oC until 
sectioning. Coronal sections (30 µm) were made on a cryostat and refrigerated in PBS 
(4oC) until immunostaining. All steps described below were carried out while gently 
rocking on an orbital shaker. All steps were carried out at room temp except for primary 
incubation. Sections were washed three times for 5 minutes each in 0.1 M PB, incubated 
in 0.3% H2O2 and 10% methanol in 0.1 M  PB for 30 min, then washed again in 0.1 M  PB 
(3 times, 5 min each). Sections were blocked for 2 hours in normal goat serum and 0.3% 
Triton-X (Sigma-Aldrich, St. Louis, MO), then incubated overnight at 4oC in rabbit anti-
mGlu5 (1:3K, Millipore, Cat. # 06-451) dissolved in blocking solution. The next day 
sections were washed three times for 10 minutes each in 0.1 M  PB, and incubated in goat 
anti-rabbit conjugated to Alexa Fluor 488 (1:1K, Invitrogen). Finally sections were rinsed 
again in 0.1 PB (3 times, 10 min each), wet mounted, and imaged on an Olympus BX51 
compound fluorescent microscope. Exposure times used for WT and KO tissue samples 
were identical and are reported in the results.
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Reagents and Drugs used in Behaviora l Exper iments : (RS) -3 ,5 -
dihydroxyphenylglycine (DHPG) was purchased from Tocris (Ellisville, MO) and 
dissolved in 0.9% normal saline on the day of the experiment. Complete Freund’s 
Adjuvant (CFA), formalin, and acetone were purchased from Sigma-Aldrich (St. Louis, 
MO). Formalin was diluted in 0.9% normal saline on the day of the experiment.
General behavioral testing conditions: All behavioral tests were conducted by an 
observer blind to genotype, in a room that was isolated from other activity, and in the 
presence of white noise. Room temperature was approximately 25oC. Mice were 
acclimated to the testing environment starting 2 to 3 hours after the beginning of the light 
cycle. Acclimation was always performed for >2 hours prior to any  behavioral testing. All 
paw injections were subcutaneous, and were made into the plantar surface of the right 
paw.
Intraplantar DHPG-Induced Heat Hypersensitivity: Heat thresholds were measured 
using a modified Hargreaves’ test  (Hargeaves et al., 1988). Mice were placed in 
individual transparent Plexiglas boxes (10L x 10W x 15H cm) on an elevated glass 
platform. A continuous radiant heat source was delivered through the glass onto the 
surface of each hind paw (IITC Life Sciences, Woodland Hills, CA), and the latency for 
animals to withdraw their paw from the glass surface was measured. The idle intensity  of 
the heat source was set to 2% and the active intensity was set  to 15% with a 20-second 
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cutoff. Baseline measurements were collected one day before collecting hypersensitivity 
measurements and animals were habituated to the testing environment separately on each 
day. For measurement of baseline thresholds 5 individual measurements were made per 
paw and averaged. Hypersensitivity was created by right hindpaw subcutaneous injection 
of 50 nmols of DHPG dissolved in normal saline. The injection volume was 10 µl of 
5mM DHPG solution. Withdrawal latencies were measured at 15, 30, 45, 60, 75, 90, 105, 
120, 150, 180, 210, and 240 minutes. Every two measurements were averaged to create 
one time point (e.g. 15 min. and 30 min. were averaged as the 30 min. time point, etc.).
Intrathecal DHPG-Induced Spontaneous Behavior: Mice were placed in individual 
transparent Plexiglas boxes (35L x 25W x 25H cm) on an elevated glass platform. DHPG 
(50 nmols dissolved in normal saline) was injected intrathecally into the lumbar spinal 
cord at the level of the iliac crest  using a Hamilton syringe and a 30 gauge needle. The 
injection volume was 5 µl of a 100 mM DHPG solution. The total time spent in 
spontaneous nocifensive behavior, defined as caudally oriented licking of the flanks, 
hindpaws, or tail, was scored in 5 minute intervals for 15 minutes following DHPG 
injection. 
Spontaneous Formalin-Induced Nocifensive Behavior: Mice were placed in 
transparent Plexiglas boxes (10L x 10W x 15H cm) on a glass surface and 10 µl of 2% 
dilute formalin solution (Sigma-Aldrich, St. Louis, MO) was injected subcutaneously into 
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the plantar surface of the right hind paw. The time spent in nocifensive behavior, defined 
as licking, lifting, or flicking of the injected paw, was scored in five-minute intervals for 
60 minutes after paw injection.
Complete Freund’s Adjuvant (CFA)-Induced Heat Hypersensitivity: Heat thresholds 
were measured using a modified Hargreave’s apparatus in the same manner as described 
for DHPG-induced heat hypersensitivity. Baseline measurements were collected one day 
before collecting hypersensitivity measurements and animals were habituated to the 
testing environment separately  on each day. For measurement of baseline thresholds 5 
individual measurements were made per paw and averaged. CFA-induced 
hypersensitivity  was created by subcutaneous injection of 10 µl of CFA (Sigma-Aldrich, 
St. Louis, MO; 1 mg/ml) into the right paw. Withdrawal latencies were measured at 30, 
60, 90, 120, 150, and 180 minutes, and 1, 2, 4, and 7 days. For time points minutes after 
injection individual measurements were made. For time points days after injection, 5 
independent measurements were averaged.
Measurement of CFA-Induced Mechanical Thresholds: Mechanical sensitivity was 
measured using nylon von Frey filaments (North Coast Medical, San Jose, CA). Mice 
were habituated in individual transparent Plexiglas boxes (10L x 10W x 15H cm) on an 
elevated wire mesh surface. Starting with the smallest filament (0.008 g), successively 
larger filaments were applied to the mouse’s hindpaw between the anterior and posterior 
foot pads. The smallest filament that evoked responses in 3 out of 5 applications was 
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taken as the mechanical threshold for each trial. Baseline measurements were collected 
one day before collecting hypersensitivity measurements and animals were habituated to 
the testing environment separately on each day. For measurement of baseline thresholds 3 
individual measurements were made per paw and averaged. For CFA-induced 
hypersensitivity  10 µl of CFA (Sigma-Aldrich, St. Louis, MO; 1 mg/ml) was injected into 
the right paw and withdrawal latencies were measured at 1, 2, and 3 hours, and 1, 3, 5, 
and 7 days. For time points hours after injection individual measurements were made. For 
time points days after injection, 3 independent measurements were averaged.
Chronic Constriction Injury Model: Mice were placed in individual transparent 
Plexiglas boxes (10L x 10W x 15H cm) on a wire mesh and spontaneous nocifensive 
behavior following the application of one drop of acetone applied to each hindpaw using 
a 1 ml syringe was measured for one minute post application. Two measurements were 
taken per paw and averaged with at least 5 minutes between applications. Spontaneous 
nocifensive behavior was defined as licking, shaking, or lifting of the hindpaw to which 
acetone was applied. Hypersensitivity  to acteone was induced via chronic constriction 
injury  of the sciatic nerve using a modified version of the model developed by  Bennett 
(Bennett & Xie, 1988) Briefly, one day  after baseline measurements mice were 
anesthetized with a combination of ketamine, acepromizine, and xylazine (KAX) 
(114mg/kg, 1.14 mg/kg, and 5.76 mg/kg KAX respectively), a small incision in the left 
thigh was made, and the sciatic nerve was exposed. Two loose ligatures of 6-0 chromic 
gut suture were tied around the sciatic nerve one millimeter apart. The wound was 
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irrigated with sterile saline and closed with 6-0 silk suture. Animals were allowed to 
recover for 3 days, then spontaneous nocifensive behavior to acetone was determined as 
described above. Acetone-induced nocifensive behavior was measured 3, 5, 7, 10, 14, 21, 
and 28 days post injury.
Spared Nerve Injury Model: Mechanical hypersensitivity following spared nerve injury 
was performed as described previously  (Alter et al., 2010). Briefly, mice were placed in 
individual transparent Plexiglas boxes (10L x 10W x 15H cm) on a wire mesh and 
baseline withdrawal latencies to Von Frey filaments were obtained from the sural nerve 
territory (lateral surface of the hindpaw) using the up-down method (Chaplan et al., 
1994). One day  after baseline measurements mice were anesthetized with pentobarbital, a 
small incision in the thigh was made, and the three main branches of the sciatic nerve 
were exposed. The common peroneal and tibial nerves were ligated with 8-0 silk suture 
and cut distal to ligation. One millimeter of distal nerve stump was removed, and the 
surgical wound was closed with 7 mm surgical clips. After 3 d of recovery, clips were 
removed. Withdrawal latency to mechanical thresholds in the sural nerve territory  was 
obtained 3, 5, 7, 10, 14, 21, and 28 days post injury. 
Data Analysis: Statistical analysis of behavioral data was performed using Prism 5.0 
(GraphPad Software, Inc.).All data collected over multiple time points from the 
spontaneous formalin and DHPG, mechanical and thermal hypersensitivity, and 
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neuropathic pain models, were statistically analyzed using a Bonferroni multiple 
comparison test after a two-way ANOVA. Summed data from these tests were analyzed 
using a two-tailed t-test when comparisons were made between two groups or a 
Bonferroni multiple comparisons tests after a one-way ANOVA when comparisons were 
made between more than two groups. Comparisons made between 2 groups at one time 
point (e.g. baseline thermal withdrawal latencies) were made using a two-tailed t-test. In 
all studies, the accepted level of significance was p < 0.05. In all figures data are reported 
as mean +/- SEM. Comparisons between baseline and later data points were done as a 
one-way ANOVA with a Dunnett’s Multiple Comparison Post Test.
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RESULTS
Verification of mGlu5 Deletion
PCR Genotyping: PCR yielded bands of expected size that were readily separable via 
agarose gel electrophoresis (data not shown).
Immunohistochemsistry: IHC of brain and spinal cord slices from WT animal identified 
by PCR demonstrated robust mGlu5 immunoreactivity in the CA1 region of the 
hippocampus, the dentate gyrus, the striatum, and the dorsal horn of the spinal cord. In 
agreement with previous reports (Jia et al., 1998), this immunoreactivity was absent in 
animals identified as KOs (Figure 1).
WT
KO
Brain Spinal Cord Figure 1: Lack of  mGlu5 Protein 
Expression in mGlu5 KO Mice.
A n t i - m G l u 5 i m m u n o s t a i n i n g 
demonstrating a lack of mGlu5 in KO 
brain and spinal cord. Anti-mGlu5 
(1:3K) primary antibody and Alexa 488 
(1:1K) secondary. Brain is imaged using 
a 4x objective and a ⅓  second exposure. 
Spinal cord is imaged using a 4x 
objective and a ½ second exposure. 
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Baseline Sensitivity of mGlu5 KO Mice to Mechanical and Thermal Stimuli: 
Baseline sensitivities to heat as measured using the Hargreaves apparatus (Figure 2a), 
evaporative cooling as measured by application of acetone (Figure 2b), and mechanical 
sensitivity (Figure 2c) as measured using nylon Von Frey filaments, were not different 
between WT and mGlu5 KO mice.
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Figure 2: Baseline Thermal and Mechanical Sensitivity are Not Altered in mGlu5 KO Mice
A) Heat Sensitivity(WT = 8.7 +/- 0.6 sec; KO = 9.7 +/- 0.6 sec;  n = 30 per group), B) cold sensitivity (WT 
= 1.2 +/- 0.13 sec; KO = 1.2 +/- 0.17 sec;  n = 26 per group for WT, 20 per group for KO), and C) 
mechanical sensitivity (WT = 0.63 +/- 0.07 g; KO = 0.76 +/- 0.06 g;  n = 20 per group) were not altered by 
a lack of mGlu5. Data are presented as averages of both paws +/- SEM.
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DHPG-Induced Nocifensive Behaviors are Reduced in mGlu5 KO Mice: Sensitivity 
to the group I mGluR agonist DHPG was decreased in KO mice as measured both by 
spontaneous nocifensive behavior following an intrathecal DHPG injection (Figure 3a), 
and by the development of hypersensitivity to a thermal stimulus following ipsilateral 
intraplantar injection of DHPG (Figure 3b). mGlu5 KO mice did not develop thermal 
hypersensitivity  following DHPG injection, whereas hypersensitivity  developed in WT 
mice at multiple time points. No changes in thermal sensitivity  were observed in the 
contralateral paw of either genotype following intraplantar DHPG injection (data not 
shown).
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Figure 3: DHPG-Induced Spontaneous Nocifensive Behavior and Thermal Hypersensitivity is 
Reduced in mGlu5 KO Mice
A) Wildtype mice have significantly greater nocifensive behavior than their KO littermates following 
intrathecal DHPG injection (2-Way ANOVA Main Effect of Genotype *** = p=0.0004; n = 4-5 mice per 
group). B) Thermal hypersensitivity following DHPG is not observed in mGlu5 KO mice, but is observed 
in their WT littermates (2-Way ANOVA Main Effect of Genotype *** = p<0.0001; n = 8 mice per group). 
Paw withdrawal latencies of WT  mice were significantly decreased from baseline at multiple time points 
(1-Way ANOVA Main Effect p=0.02). No time points were significantly different from baseline in KO 
mice. Paw withdrawal latencies of the paw contralateral to intraplantar DHPG injection were not 
significantly different (2-Way ANOVA Main Effect of Genotype p=0.90). *, **, and *** = p < 0.05, 0.01, 
and 0.001 WT compared to KO; †, †† = p<0.05, 0.01 WT time point compared to baseline.
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Formalin-Induced Nocifensive Behavior is Reduced in mGlu5 KO Mice: Nocifensive 
behavior, as measured by time spent licking or lifting the injected paw, was significantly 
decreased in mGlu5 KO mice as compared to WT littermates (Figure 4a). In addition, the 
time spent licking or lifting was significantly decreased when summed from 0 to 10 
minutes (Phase 1, Figure 4b) and from 10 to 60 minutes (Phase 2, Figure 4c).
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Figure 4: Decreased Nocifensive 
Behavior Following Intraplantar 
Formalin Injection in mGlu5 KO Mice.
A) Wildtype mice have significantly 
greater nocifensive behavior following 
intraplantar formalin injection as 
compared to their KO littermates (2-Way 
ANOVA Main Effect of Genotype ** = 
p=0.0023; 20 minute t ime point 
Bonferroni post-test ** = p<0.01; n = 5-6 
mice per group). The sum of time spent 
licking or licking in both B) Phase 1 
(0-10 minutes; unpaired t-test * = p=0.02) 
and C) Phase 2 (10-60 minutes; unpaired 
t-test * = p=0.01) was significantly less in 
mGlu5 KO mice.
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CFA-Induced Nocifensive Behavior is Reduced in mGlu5 KO Mice: Intraplantar CFA 
injection induced a unilateral hypersensitivity  to mechanical stimuli in both WT and 
mGlu5 KO mice. However, in mGlu5 KO mice recovery to baseline levels occurred 
within 1 day, whereas WT mice never recovered to baseline levels (Figure 5a).  The 
duration of hypersensitivity to mechanical stimuli was significantly  shorter in mGlu5 KO 
mice compared to WT littermates. No hypersensitivity developed to mechanical stimuli 
in the contralateral paw of mice from either genotype (data not shown). 
 Intraplantar CFA injection also induced a unilateral hypersensitivity to thermal 
stimuli in both WT and mGlu5 KO mice. This hypersensitivity was shorter lived than that 
to mechanical stimuli and both genotypes had recovered to levels not significantly 
different from baseline after 120 minutes (WT mice after 60 minutes). Genotype did not 
affect the development or recovery  from thermal hypersensitivity  (Figure 5b). No 
hypersensitivity  developed to thermal stimuli in the contralateral paw of mice from either 
genotype (data not shown). 
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CFA-Induced Mechanical 
Hypersensitivity (Von Frey)
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Figure 5: CFA-Induced Mechanical Hypersensitivity is Reduced in mGlu5 KO Mice
a) mGlu5 KO mice have significantly faster recovery from CFA-induced mechanical hypersensitivity 
compared to their WT littermates (2-Way ANOVA Main Effect of Genotype *** = p<0.0001; n = 10 mice 
per group). Paw withdrawal latencies of WT and KO mice were significantly decreased from baseline at 
multiple time points (1-Way ANOVA Main Effect p<0.0001 and p=0.0003 respectively).  Paw withdrawal 
thresholds of the paw contralateral to intraplantar CFA injection were not significantly different (2-Way 
ANOVA Main Effect of Genotype p=0.73). b) CFA-induced thermal hypersensitivity was not different in 
WT and mGlu5 KO mice (2-Way ANOVA Main Effect of Genotype p=0.86; n = 7 mice per group). Paw 
withdrawal latencies of WT  and KO mice were significantly decreased from baseline at multiple time 
points (1-Way ANOVA Main Effect p=0.01 and p<0.0001 respectively). Paw withdrawal latencies of the 
paw contralateral to intraplantar CFA injection were not significantly different (2-Way ANOVA Main Effect 
of Genotype p=0.53). 
*, *** = p < 0.05, 0.001 WT compared to KO; †, ††† = p<0.05, 0.001 WT time point compared to 
baseline; ## , ### = p<0.01, 0.001 KO time point compared to baseline.
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Neuropathic Pain Models in mGlu5 KO Mice: Hypersensitivity to evaporative cooling 
was induced in mGlu5 KO mice and their WT littermates as compared to their respective 
baselines at all time points measured post  chronic constriction injury (Figure 6a). 
However hypersensitivity to evaporative cooling was significantly  less in mGlu5 KO 
mice compared to WT littermates. No hypersensitivity developed to acetone in the 
contralateral paw of mice from either genotype (data not shown). 
 Spared Nerve Injury induced mechanical hypersensitivity in both mGlu5 KO mice 
and their WT littermates compared to their respective baselines at all time points 
measured post nerve injury (Figure 6b). There were no differences attributable to 
genotype. Hypersensitivity  was not induced in the paw contralateral to injury (data not 
shown).
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Figure 6: Neuropathic Pain in mGlu5 KO Mice
A) mGlu5 KO mice exhibit significantly less licking or lifting following acetone application (2-Way 
ANOVA Main Effect of Genotype ** = p<0.01; n = 10 - 13 mice per group).  Licking and lifting was 
significantly greater than baseline at all time points for both genotypes (WT  and KO 1-Way ANOVA Main 
Effect p<0.0001 and =0.0002 respectively). B) mGlu5 KO and WT both exhibited mechanical 
hypersensitivity after spared nerve injury. No differences were attributable to genotype (2-Way ANOVA 
Main Effect of Genotype p=0.80; n = 4 - 6 mice per group). Mechanical sensitivity was significantly less 
than baseline at all time points for both genotypes (Both WT  and KO 1-Way ANOVA Main Effect 
p<0.0001).
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DISCUSSION
 The analgesic properties of mGlu5 antagonists have been previously reported 
(Bhave et al., 2001; Walker et al., 2001a; Zhu et  al., 2004). However unambiguous 
determination of the role mGlu5 plays in the development and maintenance of chronic 
pain has been hindered by  questionable antagonist selectivity. Here I present data from 
mGlu5 KO mice that show that mGlu5 is required for the full expression of pain-related 
behaviors. When compared to WT littermates mGlu5 KO mice were found to have 
reduced nociceptive behaviors in the formalin test and following CFA-induced 
mechanical hypersensitivity. These data are in agreement with those from antagonist 
studies. Coupled with the findings presented here that the pro-algesic effects of the group 
I mGluR agonist  DHPG are markedly  reduced in mGlu5 KO mice, these findings 
strongly support the hypothesis that mGlu5 plays a role in nociception. It is interesting 
that baseline sensitivity  of mGlu5 KO mice to thermal and mechanical stimuli were 
unchanged, suggesting that mGlu5 is only  required for the development and maintenance 
of hypersensitivity and not normal sensation itself. 
 Some of the findings from mGlu5 KO mice presented here are at odds with those 
obtained from antagonist studies, however. While the results from the formalin test and 
the studies of CFA-induced mechanical hypersensitivity recapitulate the effects of MPEP 
(Zhu et al., 2004; Walker et al., 2001a), the findings that CFA-induced thermal 
hypersensitivity, and mechanical hypersensitivity  post-SNI are the same in mGlu5 KO 
mice as their wildtype littermates is at odds with results obtained using MPEP (Zhu et al., 
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2004). This may be due to the fact that previous studies using MPEP were conducted 
using rats while the studies here use mice; alternatively  it could suggest that MPEP’s 
analgesic effects are off-target for mGlu5. A direct assessment of the analgesic effects of 
MPEP in mGlu5 KO mice is presented in Chapter 3.
 The mice described in this chapter have a global deletion of mGlu5. While these 
KO mice have reductions in pain-related behaviors, mGlu5 is expressed at synapses 
throughout the pain neuraxis (Varney and Gereau, 2002), and the global nature of this 
deletion precludes the determination of the relative contribution of mGlu5 expressed at 
different synapses to nociceptive signal processing. DHPG is proalgesic when 
administered into the periphery, spinal cord, and higher brain structures and MPEP 
administration to all of these sites attenuates nociceptive behaviors (Bhave et al., 2001; 
Karim et al., 2001; Kolber et al., 2010). Therefore, it  is possible that activation of mGlu5 
at all levels of the pain neuraxis plays a role in nociception. In Chapter 5 I will report on 
findings from mice in which mGlu5 was selectively deleted only  in peripheral 
nociceptors to test the hypothesis that peripheral mGlu5 is required for the full expression 
of pain-related behaviors. 
 Results from the experiments discussed in this chapter suggest that mGlu5 might 
be a druggable target for the treatment of pain. In Chapter 3 I will present data on the 
analgesic properties of the mGlu5 antagonist fenobam, which has been tested in human 
subjects for the treatment of anxiety. Fenobam has been found to have a good safety 
profile, and thus could theoretically represent an mGlu5 antagonist suitable for treating 
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pain in human patients. Finally, mGlu5 antagonists will only be useful for the treatment 
of human pain conditions if they  also have acceptable side-effects profiles. In Chapter 4 I 
assess the possibility that  antagonism of mGlu5 may affect locomotion and motor 
coordination (Zhu et  al., 2004), which would unfortunately represent potential deleterious 
effects that could reduce the utility of mGlu5 antagonists as analgesics. 
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Chapter 3
The mGlu5 antagonist fenobam is 
analgesic and has improved in vivo 
selectivity as compared to the prototypical 
antagonist MPEP.
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INTRODUCTION 
 As discussed in chapter 2, mGlu5 KO mice have reduced sensitivity to painful 
stimuli.  Thus, mGlu5 represents a potential molecular target for the therapeutic treatment 
of pain. However, past  studies of mGlu5 antagonists have been primarily limited to pre-
clinical animal models. Research into the efficacy of mGlu5 antagonists in the treatment 
of human pain conditions would be greatly enhanced by an antagonist that has been 
shown to be safe and pharmacologically active in humans. Recently, researchers at 
Hoffmann-La Roche demonstrated that the clinically validated non-benzodiazepine 
anxiolytic fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-
imidazole-2-yl)urea] is a highly potent and selective antagonist of mGlu5 (Porter et al., 
2005). McNeil Laboratories originally developed Fenobam as a potential anxiolytic in the 
1970s and 80s, but with a then unknown molecular target. It was found to be effective at 
treating anxiety  in a double-blinded placebo-controlled clinical trial (Pecknold et al., 
1982). In that trial, and two additional trials (Pecknold et al., 1980; Lapierre and 
Oyewumi, 1982), fenobam was reported to have a good safety profile with no 
oversedation, no muscle relaxation, and no interaction with ethanol. However in a 
different phase II clinical trial (Friedmann et  al., 1980) fenobam was reported to have 
both psychostimulant side effects and be ineffective as an axiolytic. In the early 1980s, 
further development of the molecule as an anxiolytic by McNeil was discontinued. Then 
in 2005, a functional high-throughput screen and subsequent characterization by Porter, et 
al. identified fenobam as a potent, non-competitive, mGlu5 selective antagonist, acting at 
57
an allosteric modulatory  site shared with the prototypical mGlu5 antagonist 2-methyl-6-
(phenylethynyl)-pyridine (MPEP) (Gasparini et al., 1999). Interestingly, in addition to its 
anxiolytic efficacy (Ballard et al., 2005) MPEP has also been reported effective in the 
treatment of animal models of both Fragile X syndrome (FXS) (Yan et al., 2005) and 
chronic pain (Zhu et al., 2004). Fenobam was recently tested as a potential clinical 
therapeutic for FXS in humans, where it  was shown to possess beneficial clinical effect 
without significant adverse effects (Berry-Kravis et al., 2009). However, the efficacy of 
fenobam in the treatment of pain remains untested.
 Given the interest in mGlu5 as a target for inflammatory pain and the recent 
demonstration of fenobam’s efficacy as a clinically validated mGlu5 antagonist  with a 
good safety profile, I sought to compare fenobam’s analgesic efficacy  to that of MPEP in 
several in vivo models of inflammatory  pain. Here I show that fenobam, like MPEP, can 
prevent formalin-induced spontaneous pain-related behaviors and reduce Complete 
Freund’s Adjuvant (CFA)-induced thermal hypersensitivity. In addition, fenobam was 
also found to prevent spontaneous pain-related behaviors induced by the algogenic 
TRPA1 agonist mustard oil (Jordt et al., 2004). Previous pharmacokinetic analysis of 
fenobam in humans has indicated variable plasma levels (Berry-Kravis et al., 2009), thus 
I also sought to characterize the bioavailability of fenobam in both mouse plasma and 
brain tissue. Studies were also tested to determine whether tolerance to the analgesic 
effects of fenobam develop following repeat dosing. In order to establish selectivity for 
its analgesic effects on mGlu5, I also assessed the pain behaviors of mGlu5 KO mice that 
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were treated with either fenobam or MPEP. Finally, as will be discussed in detail in 
Chapter 4, I also assessed fenobam in a battery of tests designed to look for potential 
undesirable effects.
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METHODS 
Animals: Experiments were performed in accordance with the guidelines of the National 
Institutes of Health and were approved by  the Animal Care and Use Committee of 
Washington University  School of Medicine. Male Swiss-Webster mice (29.5 – 43 g) were 
purchased from Taconic. Male C57BL/6 mice used in metabolism experiments (20.0 – 
29.5 g) were purchased from Jackson Labs. For experiments involving mice lacking 
mGlu5 (mGlu5 KO; 16.5 – 22.5 g), animals were bred inhouse on a C57BL/6 
background and compared to WT littermates (Lu et al., 1997). For experiments involving 
KO animals the experimenter was blinded to genotype.  All other C57BL/6 WT mice 
used in behavioral experiments were also derived from this colony. Blinding to genotype 
was accomplished by using coded ear tag identification numbers and only breaking the 
code at the end of the experiment. Genotyping of mice bred inhouse was performed using 
standard PCR techniques as described in Chapter 2. All mice were group housed on a 
12/12-light/dark schedule with ad libitum access to food and water. 
Chemicals and Reagents: Fenobam and MPEP were purchased from Tocris (Ellisville, 
MO). Both compounds were dissolved in DMSO (100%) (Sigma-Aldrich, St. Louis, MO) 
on the day  of experiment. All intraperitoneal (i.p.) injection volumes were 20 microliters. 
Throughout all experiments the investigator was blinded to pharmacological treatment. 
Midazolam was purchased from Cerilliant (Round Rock, TX) and used as the HPLC/MS 
60
internal standard.  All other reagents were HPLC grade and purchased from Sigma-
Aldrich Co. (St. Louis, MO).
General behavioral testing conditions: Behavioral tests were conducted in the same 
general manner as described in Chapter 2.
Spontaneous Formalin-Induced Nocifensive Behavior: Mice were acclimated in a 
transparent Plexiglas box (25L x 13W x 13H cm) for 2 hours prior to any drug injection. 
Animals were then pretreated by i.p. injection with vehicle, MPEP, or fenobam. All Swiss 
Webster mice were pretreated 30 minutes prior to formalin injection. Strain differences in 
responsiveness to fenobam were noted in pilot studies and thus C57BL/6 mice were 
initially pretreated either 5 or 30 minutes prior to formalin injection to determine the 
optimal time for pretreatment in this strain (n = 4-5 per group). In all subsequent formalin 
tests involving C57BL/6 mice, including those performed with mGlu5 KO mice, vehicle 
or drugs were injected 5 minutes prior to formalin injection. Ten microliters of dilute 
formalin solution (Sigma, St. Louis, MO) was injected subcutaneously  into the plantar 
surface of the right  hind paw. Due to strain differences in formalin sensitivity (Mogil et 
al., 1999), the concentration of formalin injected into Swiss-Webster mice and C57BL/6 
mice was 5% and 2% respectively. The time spent in nociceptive behavior, defined as 
licking, lifting, or flicking of the injected paw, was scored in five-minute intervals for one 
hour beginning immediately after paw injection. For experiments comparing fenobam to 
61
MPEP in Swiss Webster mice, 30 mg/kg of each drug was administered (n=7 per group). 
For experiments intended to develop a dose response curve for fenobam in Swiss Webster 
mice, 3, 10, 30, or 100 mg/kg of fenobam was injected (n = 7-11 per group).  For 
experiments involving the testing of fenobam in C57BL/6 WT and mGlu5 knockout mice 
30 mg/kg of fenobam was injected (n=4-6 per group). For experiments involving the 
testing of MPEP in mGlu5 KO mice 30 mg/kg MPEP was injected (n = 6-9 per group).
Spontaneous Formalin-Induced Nocifensive Behavior following Chronic Fenobam 
Treatment: Male Swiss Webster mice mice were injected i.p. once per day for 5 days 
with 30 mg/kg of fenobam or vehicle (DMSO). On the 6th mice were placed in 
transparent Plexiglas boxes (10L x 10W x 15H cm) on a glass surface and mice from 
each group (chronic fenobam and chronic vehicle) were both injected with either 
fenobam or vehicle, followed 5 minutes later by intraplantar formalin injection. Thus, 
eight separate groups were analyzed, 1, 2) chronic vehicle / acute vehicle; 3, 4) chronic 
fenobam / acute vehicle; 5, 6) chronic vehicle, acute fenobam; 7,8) chronic fenobam, 
acute fenobam; with chronicity defined as 5 days. The time spent in nocifensive behavior 
was scored in five-minute intervals for 45 minutes after paw injection as described above.
Spontaneous Mustard Oil-Induced Nocifensive Behavior: Mustard oil-induced 
nocifensive behavior was performed in the same manner as that described for the 
formalin test, except 0.5% mustard oil was injected subcutaneously  instead of formalin. 
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In addition, behavioral responses were only scored for 30 minutes post mustard oil 
injection. Fenobam (30 mg/kg) or vehicle (DMSO) were injected 30 minutes prior to 
scoring mustard-oil induced behaviors (n= 4 per group).
Complete Freund’s Adjuvant (CFA) Induced Thermal Hypersensitivity: Thermal 
hypersensitivity  was measured in a manner similar to that described in Chapter 2. Briefly, 
Swiss Webster (n = 8 per group) mice were placed in individual Plexiglas containers 
(10L x 10W x 15H cm) on an elevated glass platform. A continuous radiant heat source 
was delivered through the glass onto the surface of each hind paw (IITC Life Sciences, 
Woodland Hills, CA), and the latency for animals to withdraw their paw was measured. 
The active intensity  of the heat source was set to 21%. Five baseline measurements were 
obtained 15 minutes apart  and averaged. Immediately  following baseline CFA (10 
microliters; 1 mg/ml) was injected into the plantar surface of the right hind paw. Paw 
withdrawal latency to the thermal stimulus (PWLThermal) was assessed 48 hours after CFA 
injection. One hour following assessment of post-CFA PWLThermal, animals were injected 
i.p. with fenobam (30 mg/kg) or vehicle. PWLThermal was then assessed 30 and 60 minutes 
post drug injection.
Data Analysis: Statistical analysis of behavioral data was performed in the same manner 
as described in Chapter 2.
63
Method for Quantification of Fenobam in Mouse Brain and Plasma 
Plasma and Brain Tissue Collection: Wild type Swiss Webster and C57BL/6 (n = 4 per 
group) mice were injected with fenobam (3, 10, or 30 mg/kg, i.p.) and administered an 
overdose of sodium pentobarbital (75 mg/kg) 5, 30, or 55 minutes after fenobam 
injection. Whole blood was obtained by transcutaneous cardiac puncture and plasma was 
separated via centrifugation (5 min, 4 °C, 14K G) in plasma separator tubes with lithium 
heparin (BD Microtainer). Immediately post centrifugation plasma was frozen using 
liquid nitrogen and stored at -80 °C. Brains were dissected and immediately  frozen in 
liquid nitrogen and stored at -80 °C. Whole brain homogenates were obtained by  adding 
milliQ water to brain tissue in a 2:1 (v:w) ratio and sonicating using a Branson Sonifier 
150. Brain homogenates were immediately refrozen on dry ice.
General Instrumentation: Fenobam was quantitated using LC/MS/MS. Calibrators were 
prepared in a matrix matching the samples (brain homogenates or plasma). Midazolam 
was used as the internal standard. Instrumental analysis was performed on an API 
4000QTRAP triple-quadropole mass spectrometer (Applied Biosystems/MDS Sciex, 
Foster City, CA, USA), equipped with a Turbo IonSpray Source. The Agilent 1100 HPLC 
system (Waldbronn, Germany) included a binary  pump, a thermostatted well-plate 
autosampler, and a column thermostat. An external two-way Valco valve was utilized to 
direct HPLC flow to waste before and after column elution of analytes of interest. 
Chromatographic separation was performed on a SymmetryShield RP18 analytical 
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(3.5µm, 2.1 x 30mm) column (Waters Corp., Milford, MA, USA) with a C18 guard 
(5µm, 2 x 10mm) column (Varian, Lake Forest, CA, USA) at 30oC. Before each 
injection, the needle was washed with methanol. Separate methods were used for 
determining fenobam in brain tissue and plasma.
HPLC and Mass Spec Conditions for Quantification of Fenobam in Brain Tissue: Mobile 
phase A was 20mM ammonium formate buffer, pH 5.7 and mobile phase B was 
methanol. Mobile phase was delivered at an initial condition of 2% B and a flow rate of 
0.5ml/min with the following time program: 2% B is held for 0.1 minute, followed by a 
linear gradient to 100% B between 0.1 and 1.0 minute. B is held at 100% for 0.1 minute, 
and then brought back down to initial condition of 2% between 1.1 and 2.1 minutes. The 
column is re-equilibrated with 2% B from 2.1 to 5.0 minutes. Under these conditions, the 
retention time for fenobam was 3.3 minutes and for midazolam was 3.4 minutes. The 
injection volume was 10 microliters. Both Q1 and Q3 quadrupoles of the mass 
spectrometer were optimized to unit mass resolution, and the conditions were optimized 
for each analyte. The instrument was operated in positive-ion mode with an ion spray 
voltage of 5500 volts. The curtain gas was set at 20 psi, ion source gas 1 and 2 at 20 psi, 
and the collision gas on “high”. The transitions monitored for each analyte, along with 
the analyte specific parameters are listed in Table 1.
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Calibration and Sample preparation: 50 microliters of each homogenized sample was 
pipetted into discrete wells of a 96-well 2.2ml plate. Twenty-five microliters of internal 
standard (12.5ng midazolam) was added to each sample, followed by 200 microliters of 
acetonitrile. The plate was capped and vortexed, and then centrifuged at 3000 rpm for 10 
minutes. The supernatants were transferred to a 96-well autosampler plate, and 10 
microliters was injected. Calibrators and quality  control samples were prepared along 
with experimental samples.
Calibrators, quality controls and internal standard samples: A methanolic solution of 
fenobam was prepared at  1mg/mL. Dilutions from this stock standard were prepared and 
used to make calibrator and quality control (QC) samples in brain homogenate. Brain 
homogenate calibrators contained 0.5, 2.5, 5, 10, 15, 20, 30 and 40µg/g. Brain 
homogenate QCs were made at 2.5 and 20µg/g.
HPLC and Mass Spec Conditions for Quantification of Fenobam in Plasma: Mobile 
phase A was 0.1% formic acid in water and mobile phase B was 0.1% formic acid in 
acetonitrile. Mobile phase was delivered at an initial condition of 5% B and a flow rate of 
0.4ml/min with the following time program: linear gradient between 5 and 60% B for 1.0 
minute followed by a sharp gradient to 100% B for 0.2 minute and hold at  100% B for 
0.4 min; mobile phase composition is then brought back down to initial condition of 5% 
between 1.6 and 2.1 minutes.  The column is re-equilibrated with 5% B from 2.1 to 5.5 
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minutes. Under these conditions, the retention time for fenobam was 3.4 minutes and for 
midazolam was 3.0 minutes. The injection volume was 20 microliters. Both Q1 and Q3 
quadrupoles of the mass spectrometer were optimized to low and unit mass resolution 
respectively. The instrument was operated in positive-ion mode with an ion spray voltage 
of 5100 volts. The curtain gas was set at 20 psi, ion source gas 1 and 2 at 40 and 50 psi 
respectively, and the collision gas on high. The transitions monitored for each analyte, 
along with the analyte specific parameters are listed in Table 2.
Calibration and Sample preparation: Mouse plasma samples were thawed, homogenized 
and aliquots of 25 microliters were transferred into a 96-well plate. Precipitation was 
performed using 100 microliters of acetonitrile, which contained 50ng/ml of midazolam 
(internal standard). The plate was capped and vortexed, and then centrifuged at 3000 rpm 
for 10 minutes. The supernatants were transferred to a 96-well autosampler plate, and 20 
microliters were injected for analysis. Calibrators and quality control samples were 
prepared along with experimental samples.
Calibrators, quality controls and internal standard samples: A methanolic solution of 
fenobam was prepared at  1mg/ml. Dilutions from this stock standard were prepared and 
used to make calibrator (6.0 to 16,000 ng/ml, 10 concentrations) and quality control (QC) 
samples (2 concentrations) in human plasma. Preliminary  experiments using mouse and 
human plasma had similar LC/MS/MS results.
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Table 1: HPLC-mass spectrometric acquisition parameters for brain tissue
Q1 Mass Q3 Mass Time Declustering Potential Exit Potential 
Collision 
Energy
Collision Cell Exit 
Potential
amu ms V
267.1 114 150 76 10 21 18
267.1 140 150 76 10 25 22
326.2 249.3 150 126 10 53 16
326.2 291.2 150 126 10 37 6
Table 2: HPLC-mass spectrometric acquisition parameters for plasma
Q1 Mass Q3 Mass Time Declustering Potential Exit Potential 
Collision 
Energy
Collision Cell Exit 
Potential
amu ms V
267.1 114 30 76 10 21 18
267.1 140 30 76 10 25 22
326.2 223.2 30 90 10 50 16
326.1 291.2 30 90 10 40 14
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RESULTS
Effects of Fenobam and MPEP on Spontaneous Formalin Behavior in WT Mice: I 
compared the effects of fenobam to MPEP, an mGlu5 antagonist that  has been previously 
demonstrated to reduce spontaneous behavior during the formalin test. Right hind paw 
injection of formalin resulted in a characteristic biphasic response (Figure 1a). Pre-
treatment with both fenobam (30 mg/kg i.p.) and MPEP (30 mg/kg i.p.) significantly 
reduced the time Swiss Webster mice spent licking or lifting the formalin injected paw 
during the second phase (Figure 1c). In addition pre-treatment with fenobam resulted in a 
reduction in the time spent licking or lifting during the first phase (Figure 1b).
 I next examined the effects of four different doses of fenobam (3, 10, 30, and 100 
mg/kg i.p.) on nociceptive scores during the formalin test (Figure 2a). Pre-treatment of 
Swiss Webster mice with 30 and 100 mg/kg fenobam 30 minutes prior to intra-plantar 
formalin injection significantly reduced the time mice spent licking or lifting the injected 
paw during both the first (Figure 2b) and second phase (Figure 2c).
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Figure 1: Spontaneous formalin behavior is reduced following pretreatment with fenobam or 
MPEP in Swiss Webster mice. 
A) When administered 30 min prior to intraplantar formalin injection both Fenobam (30 mg/kg,  i.p.) and 
MPEP (30 mg/kg, i.p.) significantly decrease the time spent licking or lifting the injected paw (2-Way 
ANOVA Main Effect of Drug p< 0.0001). Asterisks indicate time points where both drug treatments are 
significantly different from vehicle (n = 7 per group; *, **, *** = p< 0.05, 0.01, 0.001 respectively). 
Fenobam treated animals were significantly different from MPEP at the 5 min time point († = p < 0.05) 
B, C) Total time spent licking or lifting in the first (0-10 minutes; 1-Way ANOVA Main Effect of drug 
p=0.0018) and second phase (10-60 minutes; 1-Way ANOVA Main Effect of drug p=0.0033) 
respectively. 
Phase 2
Ve
h
Fe
no
ba
m
MP
EP
0
250
500
750
*
**
Ti
m
e 
Sp
en
t L
ic
ki
ng
 o
r
  L
ift
in
g 
In
je
ct
ed
 P
aw
 fr
om
 1
0 
- 6
0 
m
in
ut
es
 (s
ec
)
Phase 1
Ve
h
Fe
no
ba
m
MP
EP
0
100
200
300
400
***
Ti
m
e 
Sp
en
t L
ic
ki
ng
 o
r
  L
ift
in
g 
In
je
ct
ed
 P
aw
 fr
om
 0
 - 
10
 m
in
ut
es
 (s
ec
)
Spontaneous Formalin Behavior
5 10 15 20 25 30 35 40 45 50 55 60
0
50
100
150
200
250
300
Fenobam
Vehicle
MPEP
** **
***
*
†
Time after 5% formalin injection (min)
Ti
m
e 
Sp
en
t L
ic
ki
ng
 o
r
  L
ift
in
g 
In
je
ct
ed
 P
aw
 (s
ec
)
B
A
C
70
Phase 1
Veh 3 10 30 100
0
100
200
300
Fenobam (mg/kg)
***
*
Ti
m
e 
Sp
en
t L
ic
ki
ng
 o
r
  L
ift
in
g 
In
je
ct
ed
 P
aw
 fr
om
 0
 - 
10
 m
in
ut
es
 (s
ec
)
B
Spontaneous Formalin Behavior
5 10 15 20 25 30 35 40 45 50 55 60
0
50
100
150
200
250
Vehicle
10 mg/kg Fenobam
30 mg/kg Fenobam
3 mg/kg Fenobam
***
***
100 mg/kg Fenobam
† ††
Time after 5% formalin injection (min)
Ti
m
e 
Sp
en
t L
ic
ki
ng
 o
r
  L
ift
in
g 
In
je
ct
ed
 P
aw
 (s
ec
)
A
Phase 2
Veh 3 10 30 100
0
100
200
300
400
500
**
Fenobam
***Tim
e 
Sp
en
t L
ic
ki
ng
 o
r
  L
ift
in
g 
In
je
ct
ed
 P
aw
 fr
om
 1
0 
- 6
0 
m
in
ut
es
 (s
ec
)
C
Figure 2: Effect of fenobam (3, 10, 30, 
or 100 mg/kg, i.p) on spontaneous 
formalin behavior in Swiss Webster 
mice. 
A) When Fenobam is administered 30 
min prior to formalin, a minimum dose of 
30 mg/kg, i.p.  is required to see a 
significant effect (n = 7-11 per group; 2-
Way ANOVA Main Effect of Fenobam p< 
0.0001; *** = p < 0.001 for vehicle 
compared to 30 mg/kg and 100 mg/kg; †, 
††  = p < 0.05, 0.01 respectively for 
vehicle compared to 100 mg/kg). (B, C) 
Total time spent licking or lifting in the 
first (0-10 minutes; 1-Way ANOVA Main 
Effect of drug p=0.0002) and second 
phase (10-60 minutes; 1-Way ANOVA 
Main Effect of drug p<0.0001). Dunnett’s 
Post Test *,  **, *** = p< 0.05, 0.01, 
0.001 respectively as compared to 
vehicle.
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 The C57BL/6 strain of mice is often used in the generation of KO animals, and it 
is the background strain of the mGlu5 KO mice that I used in this thesis. I therefore 
examined the effects of fenobam on spontaneous formalin behavior in this strain. In 
Swiss Webster mice pretreatment with fenobam was performed 30 minutes prior to 
formalin injection. When C57BL/6 mice were pretreated with fenobam (30 mg/kg) 30 
minutes prior to formalin injection there was a reduction in formalin-induced 
spontaneous behavior 20 minutes after formalin injection as compared to vehicle, 
however the total time in the second phase was not found to be different. When C57BL/6 
mice were instead pre-treated with fenobam 5 minutes prior to formalin injection a 
significant reduction in the second phase was observed as compared to both vehicle 
injected mice and mice injected with fenobam 30 minutes prior to formalin injection 
(Figure 3).
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Figure 3: Spontaneous formalin 
behavior i s reduced fo l lowing 
pretreatment with fenobam in WT 
C57BL/6 mice. 
A) When administered 30 minutes prior 
to intraplantar formalin injection 
fenobam (30 mg/kg, i.p.) significantly 
decreased the time spent licking or 
lifting the injected paw as compared to 
vehicle at 20 minutes post injection (2-
Way ANOVA Main Effect of Fenobam 
p=0.0007; † = p<0.05). The overall time 
spent licking or lifting in the second 
phase was not reduced. When fenobam 
(30 mg/kg, i.p.) was injected 5 minutes 
prior to formalin hind-paw injection 
there was a significant reduction at A) 
multiple time points (*, *** = p<0.05, 
0.001) and C)  in the total time spent 
licking or lifting in the second phase 
(10-60 minutes; 1-Way ANOVA Main 
Effect of drug p<0.0015; Bonferroni Post 
Test p< 0.01) as compared to both 
vehicle and animals injected with 
fenobam 30 minutes prior to formalin 
injection (n = 4-5 per group).
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Effects of Fenobam on Spontaneous Mustard Oil-Induced Behavior in WT Mice: 
Mustard oil (allyl isothiocyanate), the pungent component in wasabi and horseradish, is a 
potent and selective agonist of the cation channel TRPA1 (Jordt et al., 2004). Right 
hindpaw injection elicited spontaneous licking and flinching behaviors that were 
significantly reduced by 30 minute pretreatment with 30 mg/kg fenobam (Figure 4). 
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Figure 4: Spontaneous Mustard Oil-induced Behavior is Reduced by Fenobam Pretreatment
Pretreatment with fenobam (30 mg/kg i.p.) reduces spontaneous licking and lifting induced by intraplantar 
injection of 0.5% mustard oil (n=4 per group). Fenobam or vehicle (DMSO) was injected 30 min prior to 
MO. injection. (2-Way ANOVA Main Effect of Fenobam p < 0.0001; Bonferroni Post-hoc test *** = p < 
0.001)
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Fenobam Reverses CFA-Induced Thermal Hypersensitivity in WT Mice: The effects 
of fenobam and vehicle on CFA induced thermal hypersensitivity  were compared. Forty-
eight hours following injection of CFA into the right hind paw, paw withdrawal latency  to 
a thermal stimulus (PWLThermal) relative to baseline was significantly  reduced ipsilateral 
to the injection in both groups (Fig. 5). No reduction in PWLThermal was observed in the 
contraleral paw in either group. One hour following assessment of the 48-hour-post-CFA 
PWLThermal, mice were injected i.p  with vehicle or fenobam (30 mg/kg). Fenobam, but not 
vehicle, significantly increased PWLThermal measured 30 and 60 minutes following drug 
injection as compared to their respective 48-hour-post-CFA time point (Figure 5). In the 
fenobam treated animals the post-drug PWLThermal returned to a level that was not 
significantly different from baseline, however the PWLThermal of the vehicle treated 
animals remained significantly different from baseline 30 minutes after vehicle injection 
(Figure 5). No differences were observed in the contralateral paw of any  group between 
baseline, pre-drug, or post-drug PTWLThermal (data not shown).
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Figure 5: Fenobam relieves established CFA-induced thermal hypersensitivity.
Paw withdrawal latency to a thermal stimulus was reduced 48 hours after an ipsilateral CFA injection, as 
compared to baseline.  Fenobam, but not vehicle, significantly increased thermal withdrawal latency 30 and 
60 minutes after treatment in the ipsilateral paw.  (1-Way ANOVA Main Effect of Veh p = 0.0039; Main 
Effect of Fenobam p = 0.0031; * = p<0.05 both groups as compared to baseline; †,†† = p< 0.05, 0.01 
Fenobam as compared to 48 hours post CFA; n = 8 per group).
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Fenobam Disposition in Plasma and Brain Tissue: Fenobam disposition was examined 
in both brain and plasma from C57BL/6 and Swiss Webster mice. Fenobam was readily 
detectable in plasma and brain tissue five minutes after i.p. injection in both strains 
(Figure 6a,b), and concentrations decreased thereafter. Fenobam (3 and 10 mg/kg) was 
largely cleared from both plasma and brain tissue after 30 minutes, while the highest  dose 
(30 mg/kg) remained detectable 30 minutes after injection, but was largely cleared after 
55 minutes. A brain:plasma ratio (g/g / g/ml) was calculated for the 5 minute time point 
for all three doses (Figure 6c), and was found to be significantly different in both strains 
when the 3 mg/kg and 30 mg/kg dose were compared.
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Figure 6: Fenobam brain and plasma 
concentrations. 
Swiss Webster and C57BL/6 mice were 
injected with either 3, 10, or 30 mg/kg 
fenobam i.p. and then sacrificed 5, 30, or 55 
minutes later. (a) Plasma and (b) brain 
fenobam concentrations for each animal, dose, 
and time point.  (c) A brain:plasma ratio (ml/g) 
was calculated for each animal 5 minutes after 
injection with fenobam. In both strains the 
brain:plasma ratio between the lowest dose (3 
mg/kg) and the highest dose (30 mg/kg) was 
significantly different (1-Way ANOVA Main 
Effect of Dose p<0.05; Tukey Post Test * = 
p<0.05, n = 4 per group).
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Effects of Fenobam and MPEP on Spontaneous Formalin Behavior in mGlu5 KO 
Mice: The effects of fenobam and MPEP on spontaneous formalin behavior were 
assessed in mGlu5 knockout mice in the same manner as described for Swiss Webster 
WT mice. As KO mice were bred on a C57BL/6 background, the effects of fenobam (30 
mg/kg) were also assessed on litermate WT mice. Pre-treatment with fenobam (30 mg/kg, 
i.p. 5 min. prior to formalin injection) significantly reduced the time WT littermates spent 
licking or lifting the formalin injected paw in both the first phase and second phase 
(Figure. 7 a-c). However, pretreatment with fenobam (30 mg/kg, i.p) did not alter 
spontaneous nociceptive behavior following formalin injection in mGlu5 KO mice at any 
time point (Figure 7 d-f). When mGlu5 KO mice were pre-treated with MPEP (30 mg/
kg, i.p.), there was a significant reduction in the time spent licking or lifting the formalin 
injected paw in the second phase, but not the first (Figure 7 g-i).
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Spontaneous Formalin Behavior Following
MPEP Pretreatment in KO Mice
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Spontaneous Formalin Behavior Following
Fenobam Pretreatment in mGlu5 KO Mice
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Spontaneous Formalin Behavior Following
Fenobam Pretreatment in WT Mice
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Figure 7: Spontaneous Formalin Behavior is Reduced by MPEP, but not Fenobam in mGlu5 KO 
Mice.
In C57 WT mice (a-c), but not mGlu5 KO litermates (d-f), fenobam (30 mg/kg i.p.) administered 5 min 
prior to intraplantar formalin injection significantly decreased the time spent licking of lifting the injected 
paw (2-way ANOVA Main Effect of Fenobam *** = p < 0.0001 in WT; p = 0.8513 in KO; Bonferroni Post-
hoc test *** = p < 0.001). Pretreatment with fenobam reduced both the first (unpaired t-test ** = p = 
0.0082) (b) and second (unpaired t-test p=0.049) (c) phases in WT mice.  (n = 4-6 per group.) MPEP (g-i) 
(30 mg/kg, i.p.) also reduced formalin behavior in mGlu5 KO mice when administered 30 min prior to 
intraplantar formalin injection (2-way ANOVA Main Effect of MPEP *** = p = 0.0004).  Asterisks indicate 
time point where MPEP is significantly different from vehicle (n = 6-9 per group; Bonferroni Post-hoc test 
* = p < 0.05). Pretreatment with MPEP reduced the second phase (unpaired t-test *** = p=0.0009) (i) but 
not the first (unpaired t-test p=0.18) (i).
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Tolerance Does not Develop to the Analgesic Effects of Fenobam: To test whether 
tolerance to the analgesic effects of fenobam develops over time I injected mice with 
either vehicle or fenobam (30mg/kg) for five days and then on the sixth day  injected half 
of each group (chronic vehicle and chronic fenobam) with fenobam 5 minutes prior to 
performing a formalin test. Regardless of whether they  had been treated chronically with 
fenobam or vehicle, mice acutely treated with fenobam demonstrated significantly less 
spontaneous nocifensive behavior post formalin injection when compared to chronic 
vehicle mice that were injected acutely  with vehicle (Figure 8a). Pre-treatment with 
fenobam (30 mg/kg i.p.) significantly  reduced the time mice spent licking or lifting the 
formalin injected paw during the first (Figure 8b) and second phase (Figure 8c) 
compared to 5 day Veh / Veh mice, regardless of fenobam pretreatment.
81
Spontaneous Formalin Behavior Following
Chronic Fenobam Pretreatment in WT Mice
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Figure 8: Spontaneous formalin 
behavior is reduced following five days 
of pretreatment with fenobam
A) Mice that were administered fenobam 
or vehicle for 5 days prior to the 
formalin test demonstrated significantly 
decreased time spent licking or lifting 
the injected paw when administered 
fenobam (30mg/kg) 5 minutes prior to 
intraplantar formalin injection as 
compared to mice treated with vehicle 
for 5 days and vehicle on the day of the 
experiment (2-Way ANOVA Main Effect 
of Treatment p<0.0001; Bonferroni Post 
Test **, *** = p<0.01, 0.0001 compared 
to 5 Day Veh/Veh). Both the first phase 
(b) and the second phase (c) were 
reduced (1-Way ANOVA Main Effect of 
Tr e a t m e n t p = 0 . 0 0 3 , p = 0 . 0 0 4 
respectively).  Dunnett’s Post Test *, **, 
*** = p< 0.05, 0.01, 0.001 respectively 
as compared to 5 day vehicle / vehicle 
mice. 
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DISCUSSION
 Fenobam is a potent and selective mGlu5 antagonist  that has anxiolytic properties 
in both rodents (Porter et al., 2005) and humans (Pecknold et al., 1980, 1982). Multiple 
groups have reported that pharmacological blockade of mGlu5 is effective at reducing 
nociception in several rodent pain models (Bhave et al., 2001; Karim et al., 2001; Walker 
et al., 2001; Zhu et al., 2004), however these studies were the first to report the analgesic 
properties of fenobam. In the present study  I found that i.p. administration of fenobam 
(30 mg/kg) is analgesic in three mouse models of inflammatory pain, the formalin test, 
mustard oil induce nocifensive behavior,  and the CFA-induced thermal hypersensitivity 
test. Pretreatment with fenobam reduced the time that mice from two different strains 
(Swiss Webster and C57BL/6) spent in spontaneous nocifensive behavior during the first 
and second phase of the formalin test. The effects of fenobam were dose-dependent; 30 
mg/kg was the lowest effective dose tested. These findings are similar to those seen when 
mice are pretreated with the prototypical mGlu5 antagonist MPEP (30 mg/kg). MPEP has 
been previously shown to reduce spontaneous nocifensive behaviors in the formalin test 
by several groups, with minimum effective doses in mice ranging from 10 mg/kg (Varty 
et al., 2005) to 30 mg/kg (Satow, et al., 2008). Comparison between fenobam and MPEP 
were made at a dose of 30 mg/kg because MPEP has been shown to be effective at 30 
mg/kg in reducing formalin induced nocifensive behaviors by multiple groups. These 
findings suggest that fenobam is capable of reducing both the neurogenic (phase I) and 
inflammatory (phase II) components of the formalin test. Fenobam was also found to be 
83
effective in reducing the time mice spent in nocifensive behavior following mustard oil 
injection. As both mustard oil and formalin have been shown to activate the ion channel 
TRPA1 (Jordt et al., 2004; McNamara et al., 2007), this suggests that mGlu5 may 
modulate that particular ion channel. In addition fenobam (30mg/kg) was found to relieve 
established thermal hypersensitivity induced by CFA injection. The description of 
analgesic efficacy  of an mGlu5 antagonist that has also been shown to be 
pharmacologically active and safe in humans may provide a pharmacological tool for 
assessing mGlu5 antagonists as analgesics in human clinical trials.
 Initial tests were performed in outbred Swiss Webster mice. When attempts were 
made to begin testing in C57BL/6 mice, a common strain used as a background for KO 
animals, including the mGlu5 KO mice described here and in Chapter 2, a difference was 
note in sensitivity  to the drug as compared to Swiss Webster mice. Interstrain variability 
in response to both opiate (Pick et al., 1991) and non-opiate analgesics (Wilson et al., 
2003) has been previously reported, and our findings suggest that different strains of mice 
will also exhibit variable sensitivity to fenobam. It was hypothesized that  a difference in 
fenobam concentration in brain tissue or plasma might underlie the difference in 
responsiveness between Swiss Webster and C57BL/6 mice, however both strains 
exhibited nearly identical uptake of fenobam into brain and clearance of fenobam from 
both brain tissue and plasma at  all doses and time points tested. It should be noted that 
mGlu5 is also expressed in the periphery (Bhave et  al., 2001) and the spinal cord (Varney 
and Gereau, 2002), where potential differences in fenobam concentration were not 
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assessed. While the brain:plasma ratio of fenobam 5 minutes after i.p. injection was 
found to vary  depending on dose, this variance was noted in both strains and thus cannot 
account for any  observed differences. Finally, disposition studies also demonstrated that 
fenobam is rapidly cleared from both brain tissue and plasma, such that when 
administered at 3 or 10 mg/kg the drug is nearly  absent 30 minutes after injection. This 
rapid clearance may explain why the 30 mg/kg dose was required to see analgesic effect 
in the formalin test.
 I also sought to establish that the in vivo anti-nociceptive effects of both MPEP 
and fenobam were specific for mGlu5 by testing these drugs in mGlu5 KO mice bred on 
a C57BL/6 background (Lu et al., 1997). Pretreatment with fenobam (30 mg/kg i.p.) had 
no demonstrated effects on mGlu5 KO mice when compared to vehicle treated animals. 
Of note, the second phase of the formalin test was reduced in vehicle treated KO mice 
(Figure 7F) to the same extent  as in fenobam treated WT mice (Figure 7C). This effect is 
consistent with the importance of mGlu5 in this phase of the formalin test such that 
pharmacologic and genetic knockout of mGlu5 both reduce pain related behavior to a 
similar extent (Chapter 2 Figure 5). The fact that fenobam is without effect in mGlu5 KO 
mice when compared to vehicle treated littermate mGlu5 KO controls is compelling 
evidence that fenobam is on target for mGlu5. MPEP (30 mg/kg), in contrast, was found 
to have robust, residual analgesic effects in mGlu5 KO mice. Questions regarding the 
selectivity of MPEP for mGlu5 have been noted before (Lea and Faden, 2006), and I 
report here definitive evidence that the in vivo analgesic effects of MPEP in an 
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inflammatory pain condition are not  exclusively mediated by  antagonism of mGlu5. This 
finding has specific and immediate implications for the pain field, as MPEP has been the 
primary antagonist used in assessing the role of mGlu5 in pain for over a decade (Lea and 
Faden, 2006). Previous results obtained by a multitude of research groups, must be 
considered in light of this finding. However, it is important to note that the data obtained 
with MPEP in the mGlu5 KO mice should not necessarily be taken to diminish the 
suggested role for mGlu5 in inflammatory pain. Indeed, as the present study indicates, 
fenobam is robustly  analgesic in inflammatory  pain in WT but not mGlu5 KO mice, 
suggesting its analgesic effects are selective for mGlu5. In addition, as reported in 
Chapter 2, mglu5 KO mice have reduced hypersensitivity and nocifensive behavior in 
several animal pain models. Rather than detract from a role for mGlu5 in analgesia, these 
data suggest an additional mechanism for MPEP in analgesia beyond mGlu5 antagonism.
 A major limitation of some analgesics, such as opiates, is that tolerance to their 
analgesic effects can occur over time. Tolerance to repeated daily dosing of the mGlu5 
antagonist MTEP has been demonstrated to occur in rats in the formalin test 
(Sevostianova and Danysz, 2006). To determine whether tolerance to the analgesic effects 
of fenobam develops, I injected mice daily  for 5 days with an analgesic dose of fenobam 
(30 mg/kg) or vehicle and then on the 6th day injected mice of both groups with either 
fenobam or vehicle and then performed a formalin test. Mice chronically injected with 
fenobam did not display tolerance to the analgesic effects of acute fenobam on the test 
day. Fenobam retained its analgesic efficacy in both the first and second phase of the 
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formalin test. It should be noted that this is not conclusive evidence that tolerance to 
fenobam would not develop if the drug was administered over a longer time course. 
However it  is encouraging preliminary evidence that tolerance may not be a limiting 
factor in the use of fenobam as an analgesic. 
 In conclusion, in this chapter I report that the clinically validated mGlu5 
antagonist fenobam displays robust analgesic efficacy in three mouse models of 
inflammatory pain in a manner similar to the prototypical mGlu5 antagonist  MPEP. In 
addition, I demonstrate that the in vivo analgesic effects of fenobam, but not MPEP, are 
selective for mGlu5. These findings, along with the findings from mGlu5 KO mice 
reported in chapter 2, and previous reports published in the literature, support a role for 
mGlu5 antagonists as analgesics. In addition, due to previous reports that fenobam has a 
good safety profile without oversedation, muscle relaxation, and interaction with ethanol, 
these data suggest that fenobam may represent a reasonable candidate molecule for 
testing the analgesic efficacy  of pharmacologic blockade of mGlu5 in human subjects. 
Prior to testing fenobam in human subjects it  would be important  to explore its potential 
to cause undesirable side effects. While limited studies in human volunteers (Berry-
Kravis et al., 2009), do not report any  significant adverse effects of fenobam, in Chapter 4 
I present expanded evidence regarding the role mGlu5 may play  in locomotion, motor 
coordination, and appetite by comparing the behaviors of mGlu5 KO mice compared to 
WT littermates and by  testing the effects of fenobam on locomotion, coordination, and 
appetite in both WT and mGlu5 KO mice.
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Chapter 4
The role of mGlu5 in locomotion, motor 
coordination, and appetitive behavior.
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INTRODUCTION
 Evidence from both mGlu5 KO mice presented in Chapter 2 and from the mGlu5 
antagonist fenobam presented in Chapter 3 suggest a clear role for mGlu5 in nociception. 
Activation of mGlu5 with the agonist DHPG is pro-algesic, while genetic deletion of 
mGlu5 and antagonism with fenobam result  in decreased nociceptive behaviors. These 
data provide encouraging evidence that mGlu5 may represent a viable therapeutic target 
for the treatment of pain. However, any future development of mGlu5 antagonists as 
analgesics in human patients will require drugs that are both selective for mGlu5 and 
devoid of significant adverse side effects. Adverse effects may  manifest as toxicity  of the 
parent compound or its metabolites. Unwanted effects may also result from antagonism 
of mGlu5 at sites outside the pain neuraxis. The former could theoretically be solved 
through medicinal chemistry and the design of new, non-toxic compounds. However 
deleterious effects that are due to mGlu5 antagonism at sites outside of the pain neuraxis 
would be impossible to avoid. For this reason I sought to assess both mGlu5 KO mice 
and fenobam for adverse effects that could prevent the development of mGlu5 
antagonists as analgesics. 
 Additionally, many of the measurements used to assess pain-related behavior rely  
on intact motor function. Licking, lifting, flinching, and withdrawal from stimuli all 
require normal motor responses. In Chapters 2 and 3 mGlu5 KO mice and WT mice 
treated with fenobam were found to have decreases in hypersensitivity following CFA 
injection and during the formalin test. However it is critical to verify  that confounding 
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alterations in motor coordination or locomotor behavior are not the reason for the 
perceived reductions in pain-related behaviors. Furthermore, sedation is a common dose 
limiting factor for some classes of analgesic drugs such as opiates (Melzack and Wall, 
2003, p. 389). It would therefore also be warranted to test for potential undesirable 
sedative effects of mGlu5 antagonists. In this chapter I describe the effects of both 
fenobam and genetic deletion of mGlu5 on several sensory-motor, locomotive, and 
coordination tasks.  Neither pharmacological inhibition nor genetic deletion of mGlu5 
was found to impair motor coordination. However, locomotive behaviors were increased 
in both mGlu5 KO mice and following the administration of fenobam.
 Finally, mGlu5 has been previously  shown to play  a role in appetite and energy 
balance (Bradbury et al., 2005) and mGlu5 KO mice have also been reported to weigh 
less than their WT littermates (Bradbury  et al., 2005; Xu et al., 2009). I sought to confirm 
the role of mGlu5 in weight gain and to determine if fenobam mediates any  effects on 
appetitive behavior.
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METHODS
Animals: Experiments were performed in accordance with the guidelines of the National 
Institutes of Health and were approved by  the Animal Care and Use Committee of 
Washington University School of Medicine. Male Swiss-Webster mice (6 to 8 weeks old) 
were purchased from Taconic. For experiments involving mice lacking mGlu5 (mGlu5 
KO; 6 to 8 weeks old), animals were bred inhouse on a C57BL/6 background and 
compared to WT littermates (Lu et al., 1997). For experiments involving KO animals the 
experimenter was blinded to genotype. Blinding to genotype was accomplished by using 
coded ear tag identification numbers and only  breaking the code at  the end of the 
experiment. Genotyping of mice bred inhouse was performed using standard PCR 
techniques as described in Chapter 2. All mice were group housed on a 12/12-light/dark 
schedule with ad libitum access to food and water. 
Chemicals and Reagents: Fenobam were purchased from Tocris (Ellisville, MO) and 
dissolved in DMSO (100%) (Sigma-Aldrich, St. Louis, MO) on the day  of experiment. 
All intraperitoneal (i.p.) injection volumes were 20 microliters. Throughout all 
experiments the investigator was blinded to pharmacological treatment. 
General behavioral testing conditions: Behavioral tests were conducted in the same 
general manner as described in Chapter 2.
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Sensory-Motor Battery: A series of 5 tests was performed on mGlu5 KO mice and their 
WT littermates to assess gross motor behavior and coordination. All tests were performed 
2 times.
Walking Initiation Test: Mice were individually placed in the center of a square outlined 
in white autoclave tape (21 x 21 cm) on a smooth black surface on a large table top. The 
time each mouse took to leave the square (place all four paws outside of the tape) was 
recorded. The maximum time allowed was 60 seconds. 
Ledge Crossing Task: Each mouse was tested to see how long it  could maintain its 
balance on a 0.75 cm wide plexiglass ledge without falling (60 seconds maximum). A 
score of 60 seconds was also assigned if the mouse traversed the entire 51 cm length of 
the ledge and returned to the starting point in less than 60 seconds without falling. 
Vertical Pole Descent Task: Mice were placed head upwards at the top  of a vertical metal 
rod (8 mm diameter, 55 cm height). The rod was finely textured with a file to provide a 
gripping surface. Mice were given a maximum of 120 seconds to turn 180 decrees and 
climb down to reach the bottom of the pole and place all four paws on the tabletop. Mice 
were required to reverse direction and actively  climb down. If a mouse slid down the pole 
without reversing direction or fell down the pole it was given a score of 120 seconds. 
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Platform Sit: Mice were timed for how long they could remain on an elevated circular 
platform (1 cm thick, 3 cm in diameter, 47 cm above the tabletop). A maximum score of 
60 seconds was assigned to mice that remained on the platform for that amount of time. 
Mice that climbed down from the elevated platform they were replaced on the platform. 
If they  climbed down a second time they were given a score of 60 seconds. The timer was 
stopped if a mouse fell.
Screen (Angled and Inverted): Mice were placed on a wire mesh screen (16 squares per 
10 cm, 47 cm high x 18 cm wide) set to three different inclinations, 60, 90, and 180 
(inverted) degrees. For the 60 and 90 degree inclined tests, each mouse was placed in the 
middle of the screen in a head up position and timed for how long it required to climb to 
the top or bottom of the screen. A maximum time of 60 seconds was allowed. For the 
inverted screen test, mice were placed on the screen oriented at 60 degrees, and then the 
screen was immediately inverted to 180 degrees. The time mice spent hanging on the 
screen was measured. A maximum score of 120 seconds was given to an animal that did 
not fall.
Accelerating Rotarod: An accelerating rotarod (Ugo Basile, Italy) was used to assess 
motor coordination. For experiments involving mGlu5 KOs, naive WT and KO 
littermates were given two training sessions separated by one hour. The first training 
session consisted of two trials of 120 seconds spent walking on the rotarod at a fixed 
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speed of 4 RPMs. The second training session consisted of one trial of 120 seconds at 4 
RPMs. All mice completed the first training session without falling in five attempts or 
less; all mice completed the second training session in two attempts or less without a fall. 
Latency  to fall as the rotarod accelerated from 4 RPMs to 40 RPMs over 5 minutes was 
assessed one hour after the second training session. Five consecutive acceleration trials 
were performed with 10 minutes between each trial.
 For experiments designed to assess the effects of fenobam on performance on the 
accelerating rotarod, naive Swiss Webster mice received the same training paradigm as 
described above. One hour after the second training session mice were injected i.p. with 
fenobam (3, 10, or 30 mg/kg), pentobarbital (25 mg/kg) or vehicle (DMS). Latency  to fall 
as the rotarod accelerated from 4 RPMs to 40 RPMs over 5 minutes was assessed 30 
minutes post injection. Again, five consecutive acceleration trials were performed with 10 
minutes between each trial.
Open Field Locomotor Test: Locomotor activity  was measured in an open field using a 
VersaMax Animal Activity Monitoring System (AccuScan Instruments, Columbus, OH). 
For experiments involving Swiss Webster mice, animals were habituated to the test room 
individually in Plexiglas boxes (5 x 5 x 10 inches) for 2 hours. Thirty minutes prior to the 
assessment of locomotor activity  mice were injected i.p. with fenobam (3, 10, or 30 mg/
kg) or vehicle and returned to their habituation chamber. Locomotor activity  was assessed 
by recording photobeam breaks in a 42L x 42W x 30H cm chamber for 60 minutes. Total 
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distance traveled, time spent moving, and the number of beam breaks (horizontal 
activity), were calculated for the entire chamber, as well as a perimeter (outer 8 cm ring) 
and center (inner 26 x 26 cm square) region. The percent  of time spent in the perimeter 
was also calculated as (minutes spent in perimeter / 60 minutes x 100%).
 For experiments involving naive C57BL/6 WT and mGlu5 KO mice, animals 
were acclimated to the testing room in their home cage for at least 2 hours. Locomotor 
activity was measured individually as described above and total distance traveled was 
calculated for the entire chamber. 
 For experiments designed to assess the effects of fenobam on locomotor behavior 
in  mGlu5 KO mice, animals were habituated in their home cages for at least 2 hours, and 
then injected i.p. with either 30 mg/kg fenobam or vehicle (DMSO) immediately prior to 
placement in the chamber. Animals were allowed to explore the chamber for 90 minutes 
and locomotor activity was measured individually  as described above and the total 
distance traveled was calculated for the entire chamber. 
Effects of Fenobam on Food Deprivation-Induced Food Intake: Food deprivation 
studies were performed in a manner similar to that previously  described (Bradbury et  al., 
2005). For experiments designed to assess the acute effects of fenobam on food intake 
mice were weighed and housed individually  in their home cages three days prior to food 
deprivation. The bedding was replaced with a wire mesh. On the third day mice were 
weighed again and food deprived for 24 hours starting at 1 hour after lights on until 1 
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hour after lights on the next day. Mice were then weighed again and injected i.p. with 
either 30 mg/kg fenobam or vehicle and pre-weighed food was placed onto the cage 
bottom. Food intake was measured for each mouse at 15, 30, 60, 90, and 180 minutes, as 
well as at 3 hours prior to lights off (8 hours later). In order to compensate for variation of 
body weight, mouse food intake was normalized to body weight. Mice were weighed to 
the nearest 0.1 g and food was weighed to the nearest 0.01 g. 
96
RESULTS
Effects of mGlu5 Deletion on Sensory-Motor Behavior: No differences between WT 
and mGlu5 KO littermates were noted when mice were required to sit on a platform for 
60 seconds (Figure 1a), climb down from a pole (Figure 1b), initiate movement after 
being placed in an open space (Figure 1f), or walk across a ledge (Figure 1g). No 
differences were found between the time WT and mGlu5 KO mice took to reach the edge 
of a 90 degree screen (Figure 1d), or hang inverted from the same screen (Figure 1e), 
however there was a difference when mice were required to reach the edge of a 60 degree 
screen (Figure 1c).
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Figure 1: The effects of mGlu5 Deletion on Sensory-Motor Behavior 
mGlu5 and WT littermate mice had no differences in platform sit or pole climb (a-b, on previous page; 
p=0.17, 0.97 respectively), (d) time to reach the edge of a 90 degree screen (p=.07), or (e) time hanging 
from an inverted screen (0.33). mGlu5 KO mice took significantly longer to reach the edge or bottom of a 
60 degree screen (c, 2-Way ANOVA Main Effect of Fenobam p = 0.025; No differences on Bonferroni 
Post-hoc test). All unlabeled statistics are presented as 2-Way ANOVA Main Effect of Genotype. n = 7 per 
group. 
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Figure 1: The effects of mGlu5 Deletion on Sensory-Motor Behavior (continued)
mGlu5 and WT littermate mice exhibited no differences in (f) square exit or (g) ledge crossing (p=0.39, 
0.76 2-Way ANOVA Main Effect of Genotype respectively). n = 7 per group. 
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Neither mGlu5 Deletion nor Pharmacological Inhibition Affects Performance on the 
Accelerating Rotarod: mGlu5 KO mice and their littermate controls showed no 
differences on the accelerating rotarod (4 – 40 rpm increase over 5 min over five 
consecutive trials) (Figure 2a). As compared to vehicle, fenobam injection resulted in no 
significant differences in latency to fall from an accelerating rotarod at any dose tested, 
up to 30 mg/kg (Figure 2b). No significant difference between vehicle-injected and 
fenobam-injected Swiss Webster mice was observed over five consecutive trials. In order 
to demonstrate that  a reduction in fall latency could be induced, one group of mice was 
injected with 25 mg/kg of pentobarbital, which resulted in a significant reduction in the 
fall latency in both the first and second trials, when compared to vehicle. All groups of 
Swiss Webster mice showed significant improvement in fall latency from the first to the 
fifth trial.
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Figure 2: The effects of mGlu5 Deletion on Accelerating Rotarod Performance
(a) mGlu5 and WT littermate mice had no differences in performance on the accelerating rotarod (2-Way 
ANOVA Main Effect of Genotype p=0.65, n=7 per group). (b) Fenobam administered 30 min prior to 
placement on the accelerating rotarod did not affect latency to fall at any dose tested when compared to 
vehicle. Pentobarbitol significantly decreased the latency to fall on both the 1st and 2nd trial (2-Way 
ANOVA Main Effect of Drug p<0.0001, Bonferonni Post Test **, *** = p<0.05, 0.01). All groups showed 
significant improvement from the 1st to 5th trial (2-Way ANOVA Main Effect of Time p<0.0001, Bonferroni 
Post Test ††† = p<0.001).  n = 10-12 per group.
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Both mGlu5 Deletion and Fenobam Increase Locomotor Activity in the Open Field 
Task: The open field task was used to assess the effects of genetic deletion and 
pharmacological inhibition of mGlu5 on locomotor activity. Swiss Webster mice were 
pretreated with fenobam (3, 10, and 30 mg/kg i.p.) 30 min. prior to placement in the field 
and their locomotor activity was measured. As compared to vehicle-treated animals 
fenobam produced no significant effect on spontaneous exploratory behavior at  3 and 10 
mg/kg, however at 30 mg/kg a significant increase in exploratory  behavior was observed 
in the total distance mice traveled over 60 minutes (Figure 3a,b). No significant effects 
on behaviors in the center (26 cm x 26 cm) of the open field apparatus were observed 
between the different doses (data not shown). No dose of fenobam was found to alter the 
percent of time mice spent in the perimeter versus the center (Figure 3c,d). 
 When the effects of genetic deletion of mGlu5 were examined in the open field it 
was found that drug naive mGlu5 KO mice traveled significantly farther in the open field 
over a 60 minute time period as compared to their drug naive WT littermates (Figure 
3e,f). 
 To assess whether the increased locomotor activity following fenobam 
administration was due to inhibition of mGlu5, KO mice and WT littermates were 
injected with fenobam (30 mg/kg) or vehicle (DMSO) and then immediately  placed in the 
open field for 90 minutes. There was a significant increase in the total distance travelled 
in the fenobam treated WT mice and both the vehicle and fenobam treated mGlu5 KO as 
compared to vehicle treated WT mice (Figure 3g,h).
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Figure 3: The effects of fenobam and mGlu5 Deletion on Open Field Locomotor Behavior 
When administered 30 min prior to placement in a novel open field environment, Fenobam (30 mg/kg, i.p.) 
significantly increased the total distance mice traveled as compared to vehicle (a) between 35 and 40 min 
(2-Way ANOVA Main Effect p<0.0001; Bonferroni Post Test p<0.05) and (b) as a sum total of distance 
traveled in 60 min (1-Way ANOVA p=0.0393, Dunnett’s Post Test p<0.05) (c, d) Fenobam did not decrease 
the amount of time mice spent in the perimeter (outer 8cm ring) as compared to the center (inner 26 x 26 
cm square) at any dose tested (2-Way ANOVA Main Effect of Fenobam p=0.11). (n = 10-11 per group.)
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Figure 3: The effects of fenobam and mGlu5 Deletion on Open Field Locomotor Behavior 
(continued)
Drug-naive mGlu5 KO mice traveled significantly farther compared to their WT littermates at multiple 
time points (e, 2-Way ANOVA Main Effect p<0.0001; Bonferroni Post Test *,**,*** p<0.05, 0.01,  0.001) 
and as a sum total of distance traveled in 60 min (f,  Unpaired t-test p=0.0044) n = 8 per group. (g-h) WT 
mice traveled significantly less than all other groups at multiple time points (g, 2-Way ANOVA Main Effect 
p<0.0001; Bonferroni Post Test * p<0.05) and as a sum total of distance traveled in 90 min (h, 1-Way 
ANOVA p=0.0001, Bonferroni Post Test *,**,*** p<0.05, 0.01, 0.001) Fenobam did not effect the total 
distance traveled in mGlu5 KO mice as compared to vehicle treated mGlu5 KOs (Bonferroni Post Test 
p>0.05). n = 7-8 per group.
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mGlu5 is Required for Normal Weight Gain and Feeding Behavior: Age matched 
mGlu5 KO mice weigh significantly less than their WT littermates (Figure 4a,b). The 
effects of fenobam on food intake following a 24 hour food deprivation was also assessed 
in WT Swiss Webster mice. Fenobam (30 mg/kg) administered at the time of refeeding 
significantly decreases the amount of food consumed, as compared to vehicle treated 
animals. No differences in body  weight were noted in animals prior to re-feeding (Veh = 
32 +/- 0.82 g, Fenobam = 31.73 +/- 1.25 g; unpaired T-test p=0.86). At 8 hours food 
intake of the fenobam treated mice was not different from vehicle treated animals (Veh = 
97.3 +/- 8.8 mg/g; Fenobam = 87.9 +/- 7.8 mg/g; unpaired T-test p=0.44).
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Figure 4: The effects of mGlu5 Absence and Inhibition on weight gain and  post-fasting food intake.
(a) mGlu5 KO mice weigh significantly less than their WT littermates (Unpaired t-test p=0.0012). (b) No 
differences in the age of animals was noted (Unpaired t-test p=0.58). n = 10 - 11 per group. (c) Fenobam 
(30 mg/kg) significantly decreased food intake following a 24 hour fast as compared to vehicle (2-Way 
ANOVA Main Effect of Fenobam p<0.0001, Bonferroni Post Test *, *** = p<0.05, 0.001). n = 6 per group.
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DISCUSSION
 An assessment of motor coordination, locomotive behavior, and appetitive 
behavior was performed in mGlu5 KO mice and WT mice treated with the mGlu5 
antagonist fenobam. No differences were seen in mGlu5 KO as compared to their WT 
littermates in any  sensory motor behavior task with the exception of a significant 
reduction in the time to reach the edge of a 60 degree screen. Interestingly  mGlu5 KO 
mice did not exhibit any  differences from WT controls on a 90 degree screen. The 
biological significance of a reduction in time to reach the edge of a 60 degree when all 
other tests of sensory motor function are normal is questionable, especially  when there is 
no difference when that very same screen is oriented to 90 degrees inclination. Perhaps 
more importantly, there were no differences in tests that are viewed as significantly more 
challenging, including climbing across a narrow ledge, and down from a narrow pole. 
Both of these two tasks require a mouse to navigate with limited foot purchase and 
execute complex turning behaviors without falling. A test of strength where mice were 
required to hang upside down for two minutes also yielded no differences. 
 Furthermore, no differences between mGlu5 KO and WT mice were seen on 
another test  of motor coordination, the accelerating rotarod. Fenobam treated mice also 
exhibited no differences compared to vehicle treated controls on the accelerating rotarod. 
These findings are interesting in light of findings from previous studies of MPEP and the 
related mGlu5 antagonist MTEP that have reported undesirable impairment of 
locomotion and motor coordination at analgesic doses (Zhu et al., 2004). While the 
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results presented in Chapter 4 suggest that mGlu5 is not in fact  required for normal motor 
coordination, administration of fenobam at  the analgesic dose (30 mg/kg) but not at lower 
doses (3 and 10 mg/kg) resulted in an increase in spontaneous locomotor activity in the 
open field assay. 
 This increase in locomotion is in contrast to the decreased locomotion reported 
with MPEP (Zhu et al, 2004). Previous clinical trials of fenobam in human patients 
(Friedmann et al., 1980) have reported that fenobam may have psychostimulant 
properties. It is possible that the observed increases in locomotor activity reported here 
are due to a similar psychostimulant effect that is separate from the locomotor inhibition 
seen with MPEP. It  should be noted that in figure 3a and 3b fenobam is administered 30 
minutes prior to beginning open field testing and that the increases in locomotor activity 
as compared to vehicle do not become readily apparent  until the 40 minute time point  (70 
minutes post drug injection). Based on findings from our drug disposition studies 
(Chapter 3), fenobam clearance is nearly complete after approximately one hour and 
increased locomotion is only seen after the drug is likely cleared. Therefore, it is possible, 
however speculative, that the observed increase in locomotor activity is due to the 
accumulation of fenobam metabolites and not the parent compound itself. Alternatively 
this could represent a “rebound” effect of unblocking mGlu5. 
 However, as seen in Figure 3e-h, mGlu5 KO mice exhibited increased locomotor 
activity at multiple time points when compared to WT littermates. In addition when 
fenobam injection occurs immediately  prior to placement in the open field increased 
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locomotor activity is also exhibited at multiple times points. These two findings suggest 
that the increased locomotor activity is likely due to antagonism of mGlu5. Findings that 
fenobam does not increase locomotor activity  in mGlu5 KO mice also suggest that the 
effect is mediated by mGlu5, although it is possible that ceiling effects are preventing any 
increased locomotion in mGlu5 KO mice.
 As mentioned, these findings of increased locomotor activity  are in opposition to 
those seen with MPEP (Spooren et al., 2000; Zhu et al., 2004) and the related mGlu5 
antagonist MTEP (Zhu et al., 2004), which have both been shown to reduce locomotor 
activity at analgesic doses. As the dose of fenobam that resulted in changes in locomotor 
activity is the same as that which reduced spontaneous formalin behavior (Chapter 3), it 
is possible that  the analgesic effects of fenobam will prove inseparable from certain other 
effects. However, motor coordination as measured on an accelerating rotarod was not 
affected by  fenobam at doses up to 30 mg/kg. Thus, while fenobam may increase 
locomotor activity, the potentially  more deleterious side effect of altered motor 
coordination appears to be absent at the tested analgesic dose. Furthermore the stimulant 
side effects of fenobam could actually be beneficially exploited in patients that  are also 
suffering from concurrent depression or malaise, assuming that any psychostimulant 
effects are not aversive. No significant adverse reactions were reported when three 
healthy volunteers (Berry-Kravis et al., 2009) where administered fenobam at doses of 
150 mg, so it is hoped that this will be the case. Only  further clinical testing in humans 
will tell.
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 A fascinating effect of mGlu5 deletion and pharmacological inhibition that is 
likely unrelated to analgesia is a significant effect on weight gain and post-fast feeding 
behavior. mGlu5 KO mice have been previously reported to weigh less than their WT 
littermates (Bradbury, et al., 2005; Xu et al., 2009) and I confirm this finding here. 
Differences in ad libitum food intake were not found (Bradbury, et al. 2005), so this is not 
believed to account for the differences. However both mGlu5 KO mice and mice injected 
with MPEP exhibit  significantly  less re-feeding behavior following a 14-hour fast, 
suggesting that mGlu5 does play a role in appetite and feeding behavior (Bradbury et al., 
2005). Here I report that fenobam administration also significantly  decreases post-fast re-
feeding. Fenobam’s psychostimulant properties and appetite suppressive effects should 
certainly be viewed as separate from its analgesic effects. However, rather than being 
dose limiting, it might be possible to exploit these effects to beneficial clinical use in 
certain diseases that have pain as a major symptom. Osteoarthritis is a prime candidate as 
weight loss has been associated with both a decrease in risk of developing osteoarthritis 
(Felson et al, 1997) and both weight loss and increased activity result in an improvement 
of existing osteoarthritis symptoms (Martin et al., 2001). Again, further testing in human 
patients will be necessary to know for certain.
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Chapter 5
The Pain Related Behaviors of 
Peripherally Restricted Conditional 
mGlu5 KO Mice
111
INTRODUCTION
 The findings presented above strongly suggest that mGlu5 represents a viable 
target for the treatment of pain. However, as presented in chapter 4, mice globally 
deficient in mGlu5 and WT mice treated systemically with the mGlu5 antagonist 
fenobam both exhibit altered behaviors unrelated to analgesia including increased 
locomotor activity and altered weight gain and feeding behavior. While I make the case 
that these effects may be of beneficial clinical utility  in some patients, it is also possible 
that they will be detrimental. As mGlu5 is expressed widely throughout the brain, it is 
also possible that  other centrally  mediated effects of systemically active mGlu5 
antagonists will also be detrimental. However, if mGlu5 expressed on peripheral 
nociceptive neurons was found to play  a significant role in pain transmission then it 
might be possible to develop  non-brain penetrant, peripherally restricted mGlu5 
antagonists that would be both analgesic and devoid of centrally  mediated adverse 
effects.
 While glutamate is the predominant excitatory  neurotransmitter in the CNS it has 
also been demonstrated to play a significant role as an inflammatory mediator in 
peripheral tissues. Metabotropic glutamate receptor 5 is expressed on the peripheral 
terminals of unmyelinated nociceptive neurons in the skin (Bhave et al., 2001). In 
addition, the concentration of glutamate is increased in the skin following formalin 
injection into the hind paw of the rat (Omote et al., 1998), and in the synovial fluid of 
arthritis patients (McNearney  et al, 2000), suggesting that peripherally released glutamate 
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may be able to activate peripheral mGlu5 in pain states. As demonstrated in chapter 3, 
peripheral injection of the group I mGluR agonist  DHPG into the mouse hindpaw is 
sufficient to generate thermal hyperalgesia that is absent in mGlu5 KO mice. Findings 
that peripherally administered MPEP is analgesic in both DHPG-induced hypersensitivity 
and in the formalin test (Bhave et  al., 2001; Walker et al., 2001b) support the idea that 
peripherally expressed mGlu5 could be targeted to analgesic effect. However, the 
findings presented in chapter 3 that MPEP retains analgesic activity in mGlu5 KO mice 
suggests that it may be exerting additional analgesic effect through an mGlu5-
independent mechanism. In this chapter I sought to address the question of whether 
peripheral mGlu5 is required for the full expression of pain by employing a genetic 
approach. I generated a line of conditional knockout mice lacking mGlu5 only in 
primary-afferent nociceptors. I assessed the DHPG- and formalin-induced pain related 
behaviors of these mice, as well as their performances on sensory-motor tasks. 
 These Nociceptor Specific mGlu5 (NSmGlu5) conditional knockout mice were 
generated by using a Cre-LoxP technique. Mice in which the seventh coding exon was 
flanked by  loxP (floxed mGlu5) were crossed with a Cre-expressing transgenic mouse 
line (SNS-Cre) in which Cre-Recombinase is expressed only in small diameter DRG 
neurons that express Sensory Neuron Specific Sodium Channel NaV1.8. Nav1.8 is 
selectively expressed in the subset of sensory neurons which are C-fiber nociceptors 
(Akopian et al., 1996). The resulting offspring from these crosses will only lack mGlu5 in 
peripheral sensory neurons that express NaV1.8, including virtually all unmyelinated 
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neurons. (Agarwal et  al., 2004). Initially there were technical hurdles involving Cre-
mediated recombination of mGlu5 in tissues outside of the peripheral nervous system. 
However, I report  here that NSmGlu5 mice do not differ from floxed mGlu5 littermates 
in two different pain tests, suggesting a less prominent role for peripheral mGlu5 in pain 
than was previously suggested from studies using mGlu5 antagonists.
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METHODS
NSmGlu5 Breeding Scheme: Experiments were performed in accordance with the 
guidelines of the National Institutes of Health and were approved by  the Animal Care and 
Use Committee of Washington University School of Medicine. Nociceptor specific 
conditional mGlu5 KO (NSmGlu5) mice (6 to 8 weeks old) were bred inhouse on a 
C57BL/6 background and compared to floxed mGlu5 littermates. NSmGlu5 mice were 
generated by crossing floxed mGlu5 mice with a Cre-expressing transgenic mouse line, 
in which Cre is only  expressed in small diameter DRG neurons that express Sensory 
Neuron Specific Sodium Channel NaV1.8 (SNS-Cre). Floxed mGlu5 mice were generated 
and provided by Jian Xu and Steve Heinemann (Xu et al., 2009). We used mice in which 
the Neo-cassette has been floxed out. SNS-Cre mice were generated and provided by 
Nitin Agarwal and Rohini Kuner (Agarwal et al., 2004).
 NSmGlu5 mice were generated by crossing the floxed mGlu5 mice with the SNS-
Cre mice through a series of three crosses: In Cross 1: SNS-Cre mice were crossed to 
floxed mGlu5 mice, generating 50% offspring that are heterozygous for both the Cre and 
the floxed allele (Cre/+ \\ Flox/+). In Cross 2: Cre/+ \\ Flox/+ mice were crossed to floxed 
mice generating 25% offspring that are NSmGlu5 (Cre/+ \\ Flox/Flox). In Cross 3: These 
NSmGlu5 mice were mated to floxed mice, resulting in 50% floxed mice (+/+ \\ Flox/
Flox) and 50% NSmGlu5 mice (Cre/+ \\ Flox/Flox). Floxed mGlu5 and NSmGlu5 (Cross 
3) were used to maintain the colony and produce progeny for experiments. NSmGlu5 
mice heterozygous for the NaV1.8-Cre transgene, and homozygous for the floxed mGlu5 
115
allele (Cre/+ \\ FLOXmGlu5/FLOXmGlu5) were compared to control floxed mGlu5 
littermates that retain full mGlu5 expression (+/+ \\ FLOXmGlu5/FLOXmGlu5). 
 Blinding to genotype was accomplished by using coded ear tag identification 
numbers and only breaking the code at the end of the experiment. Unless otherwise 
specified only male mice were tested. All mice were group housed on a 12/12-light/dark 
schedule with lights on at 0600 CST and ad libitum access to food and water.
PCR Genotyping: Genotyping was performed using standard PCR techniques. Two 
different genotyping protocols were used to identify  the SNS-Cre transgene and the 
presence of floxed mGlu5.
SNS-CRE Genotyping: One set of genotyping primers were used to verify  the presence of 
the SNS-Cre transgene.
Primers:
1) Forward Primer: TAT CTC ACG TAC TGA CGG TG
2) Reverse Primer: AGA CTA ATC GCC ATC TTC CAG C
Genotyping Reaction Master Mix (per reaction):
1) MilliQ Water: 19.8 µl
2) GoTaqFlexi (Promega) 5x Buffer: 5 µl
3) MgCl2 (25 mM): 1.5 µl
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4) Forward Primer: 0.5 µl
5) Reverse Primer: 0.5 µl
6) dNTPs (10 mM): 0.5 µl
7) GoTaq (Promega): 0.2 µl
8) Extracted Tail DNA - 1 µl
SNS-Cre PCR Protocol: 
Cycle 1 (1x):  Step 1: 94oC for 5 min
Cycle 2 (40x): Step 1: 94oC  for 1 min
   Step 2: 60oC for 1 min
   Step 3: 72oC for 1 min
Cycle 3 (1x):  Step 1: 72oC for 10 min
   Hold at 4oC until agarose gel separation.
Gel Separation: PCR product separation on a 1% agarose gel yields a single band of 
~500 bp in mice that express the transgene. No band is detected in mice that  did not 
possess the transgene. 
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Floxed mGlu5 Genotyping: The entire 7th coding exon of mGlu5 was flanked by LoxP as 
described and two sets of primers were used for detecting the floxed allele. 
Primers:
Set A:  1) Forward Primer  153  AGA TGT CCC ACT TAC CTG ATG T
  2) Reverse Primer  154  AGT TCC GTG TCT TTA TTC TTA GC
 3) Deletion Primer  316  AGG CGC TTC CAA AAT AGA GG
Set B:  1) Neo Primer  72  GGC TCT TTA CTA TTG CTT TAT GAT AAT G
  2) Forward Primer  126  TTG CTA GCT GAA AAG GAC GAA ACA
          3) Reverse Primer  127  TCG TTT TGA ATC TTG GGG ACA GTT AC
Genotyping Reaction Master Mix (per reaction):
1) MilliQ Water: Primer Set A: 9.4 µl ; Primer Set B: 7.9 µl
2) GoTaqFlexi (Promega) 5x Buffer: 4 µl
3) MgCl2 (25 mM): 2 µl
4) 1st Primer  if 154: 1 µl or if 72: 2.5 µl
5) 2nd Primer  (154 or 126): 1 µl
6) 3rd Primer  (316 or 127): 1 µl
7) dNTPs (10 mM): 0.4 µl
8) GoTaq (Promega): 0.2 µl
9) Extracted Tail DNA - 1 µl
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Floxed mGlu5 PCR Protocol (use for both primer sets): 
Cycle 1 (1x):  Step 1: 94oC for 3 min
Cycle 2 (35x): Step 1: 94oC for 30 seconds
   Step 2: 52oC for 30 seconds
   Step 3: 72oC for 30 seconds
Cycle 3 (1x):  Step 1: 72oC for 2 min
   Hold at 4oC until agarose gel separation.
Gel Separation: PCR product separation on a 2% agarose gel yields two different sets 
of three bands, depending on which primer set was used. 
Primer Set A: Primer 153 hybridizes ~50 bp upstream form the first loxP site, primer 
154 hybridizes ~300 bp upstream from exon 7, and primer 316 is ~240 bp 
downstream of the last loxP site. PCR using primer set A yields bands of ~200 bp, 
~270 bp  and ~320 bp  from the WT, floxed mGlu5 (with neo deletion) and del allele 
respectively. 
Primer Set B: Primer 126 hybridizes ~315 bp downstream of exon 7, primer 127 is 
~120 bp  downstream of the last loxP site, and the neo primer (72) is within the neo 
cassette, ~300 bp  upstream of the last loxP site. DNA from WT, floxed mGlu5 (with 
neo), and floxed mGlu5 (without neo) yields 217 bp, 463 bp, and 323 bp PCR 
products respectively.
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Reverse Transcription PCR rtPCR: rtPCR experiments required four steps, 1) Tissue 
harvest and isolation, 2) total RNA purification, 3) Reverse Transcription of tRNA to 
cDNA, 4) PCR of cDNA
Tissue Isolation: Mice were deeply anesthetized with a 100 µl injection of ketamine, 
acepromizine, and xylazine (KAX) (42.86 mg/ml, 8.57 mg/ml, and 1.43 mg/ml KAX 
respectively). Fresh lumbar DRGs were identified by dissecting the sciatic nerve back to 
the DRG just outside the spinal cord. DRGs were then mechanically isolated using 
iridectomy scissors, and transferred to RNA Later solution (Applied Biosystems/Ambion, 
Austin, TX). Hippocampus was isolated from fresh brain, diced into <2 mm3 pieces with 
a scalpel and transferred to RNA later solution. All tissue samples were stored at  -20oC 
until RNA purificiation. 
Total RNA Purification: RNA was recovered from tissue using an RNeasy  Micro 
Purification Kit (Qiagen, Valencia, CA). Tissue was placed into 350 microliters of Buffer 
RLT (Qiagen proprietary solution) with 1% β-Mercaptoethanol and mechanically 
homogenized with a VWR Pellet Mixer and disposable RNASE-free plastic pestal (VWR 
International, Arlington Heights, IL). Tissue was homogenized until naked-eye visible 
macroscopic pieces were no longer present. The lysate was pipetted directly  into a 
QIAshredder spin column (Qiagen, Valencia, CA) and centrifuged at 18K x g for 2 
minutes. Additional steps for RNA purification were carried out according to the Qiagen 
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RNeasy Micro Handbook (Second Edition, December 2007, pp. 27-29, steps 4 to 13). All 
pipette tips were RNASE-free.
Reverse Transcription and Genomic DNA Elimination: rtPCR was performed 
immediately following RNA purification using a QuantiTect Reverse Transcription Kit 
(Qiagen, Valencia, CA). Four microliters of total RNA were used as template. The 
protocol was carried out according to the Qiagen QuantiTect Reverse Transcription 
Handbook (January 2009 Edition, pp. 12-13). cDNA was stored at -20oC until performing 
PCR reactions. 
PCR Genotyping: Two different  primer sets were used, one directed at exon 1, which is 
deleted in the global mGlu5 KO mice described in Chapter 2, and one directed at exon 7, 
which is flanked by LoxP in the floxed mGlu5 mice generated by Xu et al. (2009). 
Primers:
Set 1:  Forward Primer is in Exon 1, Reverse is in Exon 7
 Forward Primer 1: GAG GGT TGT ACC TTC GGA TG
 Reverse Primer 1: CCA GTA TCT TCG ATG GGG TG
Set 6: Forward Primer is in Exon 6, Reverse is in Exon 8
 Forward Primer 6: CTG GCC CAC TGA CGA CTT
 Reverse Primer 6: CCC AGA ATG AGA AGA GCA C
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Genotyping Reaction Master Mix (per reaction):
1) MilliQ Water: 13.8 µl
2) GoTaqFlexi (Promega) 5x Buffer: 4 µl
3) MgCl2 (25 mM): 2.5 µl
4) Foward Primer: 1 µl
5) Reverse Primer: 1 µl
6) dNTPs (10 mM): 0.5 µl
7) GoTaq (Promega): 0.2 µl
8) cDNA - 1 µl
PCR Protocol (use for both primer sets):
Cycle 1 (1x):  Step 1: 94oC for 4 min
Cycle 2 (35x): Step 1: 94oC for 45 seconds
   Step 2: 55oC for 45 seconds
   Step 3: 72oC for 45 seconds
Cycle 3 (1x):  Step 1: 72oC for 5 min
   Hold at 4oC until agarose gel separation.
Gel Separation: PCR product separation on a 2% agarose gel yields two different sets 
of bands, depending on which primer set was used. 
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Primer Set 1: The forward primer hybridizes within the 0.4 kb portion of exon 1 that 
has been deleted from the global mGlu5 KO mice. It is approximately  75 base pairs 
from the exon 1 and 2 junction. The reverse primer hybridizes in exon 7, 
approximately 20 base pairs from the exon 6 and exon 7 junction. Primer set 1 yields 
an ~1160 bp product in WT mice and no product in global mGlu5 KO mice derived 
from John Roder’s colony (See Chapter 2). 
Primer Set 6: The forward primer hybridizes in Exon 6, approximately 5 bp from the 
exon 6 and exon 7 junction. The reverse primer hybridizes in Exon 8, approximately 
25 bp from the exon 7 and exon 8 junction. Primer set 6 potentially yields two bands, 
one of ~1100 bp  if the floxed exon (exon 7) is present, and one of ~160 bp if the 940 
bp floxed exon has been excised.
Reagents and Drugs used in Behavioral Experiments: DHPG and formalin were from 
the same sources and prepared in the same manner as described in Chapter 2.
General behavioral testing conditions: Behavioral tests were conducted in the same 
general manner as described in Chapter 2.
Accelerating Rotarod and Open field Locomotor Test: The accelerating rotarod task 
and open field locomotor tests were performed in the same manner as used to test mice 
globally deficient in mGlu5 as described in Chapter 4.
123
Intrathecal DHPG-Induced Spontaneous Behavior: Spontaneous i.t. DHPG-induced 
behavior was assessed in the same manner as described in Chapter 2.
Spontaneous Formalin-Induced Nocifensive Behavior: Spontaneous formalin induced 
nocifensive behavior was assessed in the same manner as described in Chapter 2 with one 
exception. Since spontaneous nocifensive behavior was generally  absent from 45 to 60 
minutes in previously tested animals, behaviors were scored only for 45 minutes, instead 
of 60 minutes.
Data Analysis: Statistical analysis of behavioral data was performed in the same manner 
as described in Chapter 2.
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RESULTS
Verification of Peripherally Restricted Deletion of mGlu5
PCR Genotyping: Genotyping from tail DNA was expected to produce bands at ~200 bp 
and ~270 bp corresponding to WT and floxed mGlu5 genotype mice respectively. 
However, a third band was also seen at ~320 bp in some mice (See Figure 1). This ~320 
band corresponds to a genotype where exon 7 of mGlu5 has been excised (Xu et al, 
2009). Initially genotyping was performed using a different set of primers (Xu et al, 
2009), and as such this extra band was not immediately discovered. PCR of tail DNA 
taken from several mice that were used as breeders in this colony were later found to 
produce a band at ~320 bp. Eleven of the first 53 breeders that were set up  had a band at 
~320 bp. At least one mouse in 9 out 21 matings in the colony (42.9% of all matings) had 
a band at ~320 bp. The presence of the CRE transgene did not affect whether the band at 
~320 bp  was seen. Mice B and D had the SNS-Cre transgene, while mice A and C did not 
(data not shown).  Some mice that were CRE-negative were found to have had a band at 
~320 bp. Whether the CRE-transgene was present in the mother or the father did not 
affect the appearance of a band at ~320 bp in offspring.
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A DCB
Figure 1: Gel of a PCR from Floxed mGlu5 Genotyping. 
A representative gel showing PCR results from genotyping tail DNA from NSmGlu5 mice and their floxed 
littermates. The bands on the left labelled WT and Flox are control DNA from animals previously 
genotyped. Note the two bands in lane A and B corresponding to ~270 and ~320 bp respectively. Only the 
~270 bp band is present in lanes C and D. Mice from A and B are interpreted as having one copy of the 
floxed mGlu5 allele and one copy where the floxed section has been deleted to make a global KO allele. 
Mice in lane C and D are interpreted as being homozygous floxed. Note that mice A and C did not have the 
SNS-Cre Transgene, while mice B and D did. Thus, mouse A and B are actually heterozygous for mGlu5, 
while mouse C is a true Flox mGlu5 mouse with no mGlu5 deletion at either locus and mouse D is an 
NSmGlu5 mouse, homozygous for the floxed mGlu5 and possessing the SNS-Cre transgene.
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rtPCR: PCR amplification of cDNA from mouse DRGs and hippocampus was performed 
to detect the different mGlu5 RNA species present in those tissue types. Two different 
sets of primers were used to detect deletion of mGlu5. Figure 2 is a schematic of the 
exons that make up the mGlu5 cDNA and the locations of the primers in that cDNA. The 
four animals that are labelled A-D in Figure 1 were assessed for different cDNA species 
by rtPCR (Figure 3). Animals that had a ~320 bp band in the genotyping PCR (A and B) 
exhibited two bands when rtPCR was performed with primer set 6, one at  ~160 bp  and 
one ~1100 bp. These two bands were seen in both DRGs and hippocampus (Figure 3). 
Animals that did not have the band at ~320 bp (C and D) only  had two bands when rtPCR 
was performed in DRGs (Figure 3). When rtPCR was performed on additional mice, 
including WT and global mGlu5 KO mice, two bands were only seen using primer set 6 
in NSmGlu5 mice (Figure 4). Using primer set 1, all mice exhibited a band of ~1100 bp 
except global mGlu5 KO mice, where no band was found in either DRGs or brain 
(Figure 4). WT, floxed mGlu5, and NSmGlu5 mice only had a band at  ~1100 bp using 
primer set 6 (Figure 4). All mice used for behavioral experiments described below were 
verified to not have a band at ~320 bp on genotyping PCR.
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6F
6R1R
Global Deletion
Floxed Exon (940 bp)
1F to 1R = 1163 bp
6F to 6R = 1105 bp or 165 bp (if oxed out)
1F 6F
6R1R
250 bp
250 bp
Figure 2: Schematic of mGlu5 cDNA with PCR Primer Binding Sites
A graphical representation of the mGlu5 cDNA along with its UTRs. Each color change represents a 
different exon. The 5’-UTR is white, the 1st exon is teal,  etc. The red box represents the 95 bp addition 
seen in the b splice variant of mGlu5 (Joly et al., 1995). All exons are to scale. Primer set 1 primers are 
located in the 1st exon (1F) and the 7th exon (1R),  1163 bp apart. Primer set 6 primers are located in the 6th 
exon (6F) and 8th exon (6F). The floxed exon is 940 bp, so primer set 6 will produce two different sized 
products depending on the presence (1105 bp) or absence (165 bp) of exon 7.
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Figure 3: rtPCR of NSmGlu5 and Floxed mGlu5 mice
Representative PCR of cDNA from DRGs and hippocampus of mice with and without the ~320 bp band 
detected on genotyping PCR. A and B demonstrate the 320 bp band and also show two bands, one at ~160 
bp and one at ~1100 bp in both hippocampus and DRGs. C and D did not demonstrate the 320 bp band and 
hippocampus from these mice only show one band at ~1100 bp. Note that mouse C also did not have the 
SNS-Cre transgene and is the only mouse not to show a band at ~160 bp in the DRG. Lanes labelled “1” 
are DNA generated using primer set 1 (single arrow head). Lanes labelled “6” are DNA generated using 
primer set 6 (double arrow head). Other lanes are generated using primer sets not described.
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WT BrainDRG Flox BrainDRG NS - Brain
NS - DRG KO BrainDRG Water
1 61 6 1 61 6
1 61 6 1 61 6
1 6
Figure 4: rtPCR of WT, floxed mGlu5, NSmGlu5, and mGlu5 KO mice
Representative PCR of cDNA from DRGs and brain of all mice described in this thesis. The “NS” mouse is 
a mouse that produced a band at ~320 bp when genotyping for the floxed allele was performed, suggesting 
that it has an allele that is a global mGlu5 deletion. Note the two bands in the brain of this mouse. All mice, 
except for the mGlu5 KO mouse exhibited a band at ~1100 bp using Primer Set 1. All mice produced a 
band at ~1100 bp using primer set 6. Only the “NS” mouse produced a ~160 bp band using primer set 6. 
Lanes labelled “1” are DNA generated using primer set 1 (single arrow head). Lanes labelled “6” are DNA 
generated using primer set 6 (double arrow head).  Other lanes are generated using primer sets not 
described.
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Peripheral mGlu5 Deletion Does not Affect Open Field Locomotor Activity: 
NSmGlu5 mice and their floxed littermate controls did not exhibit any  difference in the 
total distance travelled in the open field over a 60 minute period (Figure 5). 
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Figure 5: The effects of Conditional mGlu5 Deletion on Open Field Locomotor Behavior 
NSmglu5 mice did not differ from floxed littermates when allowed to freely explore an open field for 60 
minutes (2-Way ANOVA Main Effect p=0.9106). (n = 4-6 per group.)
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Conditional mGlu5 Deletion Does Not Affect Performance on the Accelerating 
Rotarod: NSmGlu5 KO mice and their littermate controls showed no differences on the 
accelerating rotarod (Figure 6).
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Figure 6: The effects of Conditional mGlu5 Deletion on Accelerating Rotarod Performance
NSmglu5 mice did not differ from floxed littermates in performance on the accelerating rotarod (2-Way 
ANOVA Main Effect of Genotype p=0.75, n=4-6 per group).
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DHPG-Induced Nocifensive Behaviors in NSmGlu5 Mice: Both NSmGlu5 and floxed 
littermate mice exhibited nocifensive behavior following an intrathecal injection of 
DHPG. There were no differences noted due to genotype (Figure 7). 
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Figure 7: DHPG-Induced Spontaneous Nocifensive Behavior in NSmGlu5 Mice
NSmGlu5 mice did not differ from floxed littermates in time spent in nocifensive behavior following 
intrathecal DHPG injection (2-Way ANOVA Main Effect of Genotype p=0.3961; n = 4-6 mice per group).
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Formalin-Induced Nocifensive Behavior is Not Reduced in NSmGlu5 Mice: 
Nocifensive behavior, as measured by time spent licking or lifting the injected paw, was 
not found to be different when NSmGlu5 mice were compared to WT littermates (Figure 
8a-c).
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Spontaneous Formalin Behavior
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Figure 8: Nocifesnive Behavior 
Following Intraplantar Formalin 
Injection in NSmGlu5 Mice.
A) NSmGlu5 and floxed litermates did 
not differ in their responses to formalin 
injection (2-Way ANOVA Main Effect of 
Genotype p=0.0585; n = 4-6 mice per 
group). The sum of time spent lifting or 
licking in both B) Phase 1 (0-10 minutes; 
unpaired t-test p=0.21) and C) Phase 2 
(10-60 minutes; unpaired t-test p=0.09) 
was not different when NSmGlu5 mice 
were compared to floxed littermates.
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DISCUSSION
 In chapters 2 and 3 I present data from genetic and pharmacological studies that 
suggest a role for mGlu5 in the development of pain. However, data presented in Chapter 
4 show that targeting mGlu5 for its analgesic potential may also induce increased 
locomotor behavior and alterations in appetite and food intake, suggesting centrally 
mediated effects unrelated to analgesia. In this chapter I assessed two pain related 
behaviors in peripherally restricted conditional mGlu5 KO mice, in which mGlu5 is 
putatively deleted only in small diameter nociceptive neurons expressing the sodium 
channel NaV1.8.
 NSmGlu5 mice were not found to be different from floxed control mice in two 
mouse pain models, the formalin test  and intrathecal DHPG-induced spontaneous 
nociception. Both NSmGlu5 and floxed littermate controls exhibited a typical two phase 
formalin response and were not different from each other either in the first ten minutes 
(phase 1) or the last 35 (phase 2). In addition, both groups of mice exhibited spontaneous 
nocifensive behavior following an intrathecal injection of DHPG. When quantified these 
behaviors were not found to be different between the two groups.
 Previous studies have suggested that intrathecal DHPG injection causes 
spontaneous nocifensive behavior due to direct effects on spinal cord dorsal horn neurons 
(Karim et al., 2001). In Chapter 2 I presented data that demonstrated a significant 
reduction in nocifensive behavior following DHPG injection in global mGlu5 KO mice 
compared to WT littermate controls. NSmGlu5 mice should only have mGlu5 deleted 
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from peripheral nociceptors and not spinal cord neurons. Thus the finding that deleting 
mGlu5 only from peripheral nociceptors does not affect DHPG-induced spontaneous 
behavior, combined with data from the global mGlu5 KO mice presented in Chapter 2, 
suggests that  intrathecal DHPG is primarily  exerting its effects on dorsal horn spinal cord 
neurons or large diameter NaV1.8-negative DRG neurons. While there is some evidence 
that mGlu5 expressed on the central presynaptic terminals of peripheral nociceptive 
neurons may contribute to central sensitization by modulating TRPV1 (Kim et al., 2009), 
the data I present above suggests that  presynaptically expressed mGlu5 in NaV1.8- 
positive neurons does not significantly contribute to spontaneous nocifensive behaviors 
induced by intrathecal DHPG, at least not at the dose (50 nmols) that I have tested here. 
 The finding that NSmGlu5 mice do not have significantly reduced nociceptive 
behaviors in the formalin test is somewhat surprising. Peripheral injection of MPEP 
reduces formalin-induced spontaneous nociceptive behaviors only when injected into the 
ipsilateral and not the contralateral paw (Bhave et al., 2001), suggesting a peripheral 
mechanism of action. This result was taken to suggest that peripherally  expressed mGlu5 
might be required for the full expression of pain and it  was expected that NSmGlu5 mice 
would exhibit reduced responses to formalin. However, the data from the NSmGlu5 mice 
presented in this chapter suggests that peripheral mGlu5 in NaV1.8-positive neurons is 
not necessary  for formalin induced spontaneous nocifensive behavior. It  is quite possible 
that peripheral mGlu5 plays a more limited role in nociception than that suggested by 
previous antagonist  studies. It should also be noted that the NSmGlu5 mice tested here 
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should lack peripheral mGlu5 following functional Cre-Recombinase expression at P0 
(Agarwal et al., 2004) and the possibility of compensation due to a lifetime of an absence 
of peripheral mGlu5 could possibly account for the lack of an effect on the formalin test. 
However I have no direct evidence to suggest that compensation is occurring here, and as 
such the most parsimonious explanation for the formalin test findings presented above is 
that peripheral mGlu5 plays a more limited role in formalin-induced nociception than was 
previously  thought. This may suggest  a more limited role for peripheral mGlu5 in other 
pain-related behaviors as well. 
 Compensation is but one peril of using genetically  modified organisms. When 
using a Cre-Recombinase / LoxP strategy to excise a gene in a tissue-specific manner any 
deviation from the expected Cre-recombinase expression pattern may result in a 
misinterpretation of the results. This is specifically illustrated in the findings presented 
above that some NSmGlu5 mice exhibit Cre-mediated excision of the 7th exon of mGlu5 
in tissues besides the DRGs. Cre transgenes can effect excision of floxed gene sequences 
in the germline if the Cre-allele and floxed allele are inherited from the same parent 
(Schmidt-Supprian and Rajewsky, 2007). Unfortunately, due to the desire to avoid testing 
mice globally heterozygous for mGlu5, the breeding strategy that we chose to generate 
the NSmGlu5 mice explicitly uses parents that express both alleles. Thus, it is likely  that 
the mGlu5 excision I have found in the brain may  be due to cre-mediated excision of 
mGlu5 in the gametes. The data presented above regarding the locomotor, rotarod, and 
pain-related behaviors of NSmGlu5 mice use only mice that do not demonstrate a 
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genotyping PCR band at ~320 bp. This would suggest that they do not have a germline 
excision of mGlu5, however Cre-fidelity  in other tissues has not been directly assessed. 
Thus, it  is also possible that the lack of a difference between NSmGlu5 mice and their 
floxed littermates is due to undetected ectopic Cre-expression which could result in a 
mosaic expression of mGlu5. Future users of the NaV1.8 Cre mice developed by Agarwal 
and Kuner will have to take care to check for cre-mediated excision of their target  in 
unexpected tissue. It may  be advisable that future experiments designed to test the effects 
of peripheral mGlu5 in nociception use a different line of mice in which Cre expression is 
driven by a knock-in to the NaV1.8 locus (Stirling et al., 2005). A breeding strategy in 
which mGlu5 het / Cre mice were crossed with homozygous mGlu5 floxed animals 
would keep the Cre- and floxed- alleles from being inherited from the same parent. 
However half of the offspring generated in this way  would be globally heterozygous for 
mGlu5, which could potentially confound the interpretation of behavioral experiments.
 Overall the data presented in this chapter indicate that peripheral mGlu5 may not 
be as encouraging a target for the treatment of pain as was previously hoped. However, to 
paraphrase Bud Craig from the introduction, a mouse is not a human. Indeed there are 
well known examples of the failed translation into human patients of analgesics predicted 
to be efficacious by animal models (Mogil et al., 2010). The converse of that axiom is 
that failed studies in mice do not necessitate failure in man. While these data presented 
above would not advocate for the rational design of peripherally  restricted mGlu5 
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antagonists as analgesics, should serendipity provide one (for example see Porter et al., 
2005), the testing of its analgesic properties would be warranted.
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Chapter 6
Summary and Future Directions
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mGlu5 is Required for the Full Expression of Pain-Related Behaviors
 Overall, the findings presented in this thesis strongly support a role for mGlu5 in 
the development of pain and suggest that antagonism of mGlu5 may  represent a viable 
treatment option for human pain conditions. As presented in Chapter 2, intrathecal and 
intraplantar injections of the group I mGluR agonist DHPG induce significantly 
decreased nociceptive responses and hypersensitivity in mGlu5 KO mice, suggesting that 
DHPG is exerting its pro-algesic effects by activating mGlu5. In addition, mGlu5 KO 
mice have decreased spontaneous nocifensive responses induced by intraplantar injection 
of formalin. Furthermore, when compared to WT littermates, these mice exhibit a faster 
recovery to baseline mechanical thresholds following injection of the inflammatory  agent 
CFA.
 In Chapter 3 I demonstrate that the mGlu5 negative allosteric modulator fenobam 
reduces nocifensive behavior in WT mice. In addition, fenobam is found to be without 
analgesic effect in the formalin test when administered to mGlu5 KO mice, suggesting 
that fenobam’s analgesic properties are due to antagonism of mGlu5. These results 
suggest that mGlu5 is required for the full expression of pain, and imply  that allosteric 
modulation of mGlu5 may have therapeutic effect in the treatment of pain in humans. 
 As discussed above, mGlu5 is expressed throughout the pain neuraxis. One of the 
goals of this thesis was to determine the role that  mGlu5 expressed in peripheral 
nociceptive neurons plays in pain. In Chapter 5 I assessed the pain-related behaviors of 
mice in which mGlu5 had been deleted exclusively from peripheral nociceptors. In 
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contrast to the global mGlu5 KO mice, pain-related behaviors were not found to be 
altered in peripherally  restricted mGlu5 KO mice, suggesting that peripheral mGlu5 
expressed in C-fiber nociceptors is not required for the development of pain. This finding 
also implies that mGlu5 expressed within the central nervous system or large diameter 
DRG neurons plays an important role in pain.
 The finding presented in Chapter 2 that spontaneous nociceptive behaviors induced 
by intrathecally injected DHPG are reduced in mGlu5 KO mice implies that activation of 
mGlu5 within the spinal cord contributes to the development of pain. Additionally, 
important roles for mGlu5 in pain have also been suggested within the amygdala, and 
specifically within the laterocapsular division of the central nucleus (CeLC), which 
receives pain projection neurons from the spino-parabrachio-amygdaloid pathway. 
Multireceptive (MR) neurons within the CeLC respond to low-intensity stimuli, but are 
more robustly activated by  noxious stimuli. DHPG-induced activation of group I mGluRs 
within the CeLC potentiates the responsiveness of amygdala MR neurons to innocuous 
and noxious stimuli both in naive animals and following kaolin/carrageenan-induced 
arthritis (Ji & Neugebauer, 2010; Li & Neugebauer, 2004). In addition, following arthritis 
induction, MPEP both inhibits the responses of CeA neurons, and reduces the 
vocalizations of awake animals following stimulation of the injured knee (Han & 
Neugebauer, 2005). Administration of DHPG into the CeLC is also sufficient to induce 
mechanical hypersensitivity and injection of MPEP into the CeLC is able to reverse 
formalin-induced mechanical hypersensitivity  (Kolber, et  al., 2010). MPEP has been 
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found to have residual analgesic efficacy in mGlu5 KO mice (Chapter 3), indicating that 
it may be mediating this effect in an mGlu5 independent manner. However, formalin-
induced mechanical hypersensitivity  is also significantly  reduced by genetic ablation of 
mGlu5 selectively within the CeLC (Kolber, et al., 2010), suggesting that CeLC 
expressed mGLu5 is necessary for the development of hypersensitivity. It is therefore 
possible that the analgesic effects observed following systemic injections of the mGlu5 
antagonist fenobam are due to inhibition of both spinal and amygdalar mGlu5. mGlu5 
activation within the spinal cord and the CeLC has been shown to activate the 
intracellular signaling molecule ERK (Karim et al., 2001; Kolber et al., 2010). In turn, 
ERK activation within the spinal cord and CeLC has been demonstrated to be required 
for the full behavioral responses to algogenic stimuli (Karim et al., 2001; Carrasquillo & 
Gereau, 2007). These findings further implicate mGlu5 as an important cellular 
component of pain modulation within the spinal cord and the amygdala. 
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The Translation from Pre-clinical Animal Models to Human Trials
 While the findings discussed above support  the targeting of mGlu5 for the 
treatment of pain, additional studies also warrant caution in using mGlu5 antagonists as 
analgesics due to the potential for adverse side effects. Locomotor and learning effects 
were reported in mice and rats administered analgesic doses of fenobam (Chapter 4 and 
Jacob et al., 2009). Additionally, findings from mGlu5 KO support a role for mGlu5 in 
normal locomotor activity and in appetitive behavior and weight gain. mGlu5 KO mice 
were found to have significantly  higher locomotor exploratory behavior when compared 
to WT mice and the mGlu5 antagonist fenobam increased locomotor behavior in WT 
mice compared to vehicle injected mice. In addition, fenobam significantly  suppressed 
food intake following a 24 hour fasting period, suggesting that fenobam may decrease 
appetite. 
 However, mGlu5 KO mice were found to be indistinguishable from their WT 
littermates in motor coordination tasks. Also, an analgesic dose of fenobam did not affect 
motor coordination assessed using an accelerating rotarod. While the alterations in 
locomotor behavior and food-intake are clearly off-target, they may not sufficiently 
deleterious to prevent the use of fenobam as an analgesic. Finally, no side-effects were 
reported in 3 healthy human volunteers orally  administered 150 mg of the fenobam 
(Berry-Kravis et al., 2009), suggesting that the analgesic effects of fenobam may be ready 
for assessment in human subjects. 
  Fenobam is not the only mGlu5 antagonist that could potentially be tested in 
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humans, and several drug companies have lead compound mGlu5 antagonists in early 
clinical testing. For example, Addex Pharmaceuticals has begun conducting trials of one 
of its lead mGlu5 NAM compounds, ADX10059, and has reported efficacy as a treatment 
for migraine in a phase 2A trial (Keywood, 2008). ADX10059 (750 mg total dose) was 
reported to have a good safety profile in a separate trial examining its utility  as a 
treatment for gastro-esophageal reflux disease (Keywood et al., 2009). However, a phase 
2B trial involving cumulative doses of ADX10059 (up to 200 mg per day) has been 
recently  terminated due to a higher than expected incidence of abnormal liver functions 
tests (ClinicalTrials.gov ID: NCT00820105, accessed March 3, 2010). While the data 
presented in this thesis suggests that  mGlu5 antagonists may have utility in the treatment 
of chronic pain conditions, clearly carefully conducted future testing in humans will be 
necessary  to ascertain whether potential analgesic effects are separable from dose-
limiting side effects.
 In addition to treating migraine, mGlu5 antagonists may have a role in the treatment 
of other pain conditions, such as post-operative pain, arthritis, and fibromyalgia. mGlu5 
antagonists may  be useful as mono-therapies, or in combination. For example, it  is 
possible that ligands acting at mGluRs may be useful as adjuvants for opiate analgesia. 
NMDA receptor antagonists are known to attenuate the development of morphine 
tolerance (Marek et al., 1991) and several studies have indicated that ligands for group I 
and II mGluRs may have similar effects. Systemic administration of the mGlu5 
antagonist MPEP and the group II mGluR agonist LY379268 have been shown to 
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improve the analgesic efficacy of morphine and reduce the development of tolerance in a 
model of neuropathic pain (Kozela et  al., 2003; Osikowicz et al., 2008). Further studies 
will be necessary  to expand upon these initial studies and to determine whether mGluR 
ligands may act as adjuvants for other known analgesics, such as non-steroidal anti-
inflammatory agents.
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The Heat/Capsaicin Trial as a Method for Assessing Fenobam as an Analgesic
 In addition to conducting clinical trials in patients, human experimental pain 
models play  an important role in the assessment of the analgesic properties of novel 
compounds. Predictive and non-invasive pain models can facilitate the transition from 
pre-clinical testing to more expensive clinical trials by  providing a cost-effective way to 
assess analgesic efficacy in a limited number of healthy volunteers. Future studies should 
be performed that assess the ability of fenobam to modulate human pain in healthy 
volunteers, thus expanding the pre-clinical data into human subjects. 
 While substantial pre-clinical data exist indicating that negative allosteric 
modulators of mGlu5 may mediate their analgesic effects via prevention or reversal of 
central sensitization in rodents, no findings that directly test  this hypothesis in human 
subjects have been published. One way to address this question would be to test the 
ability  of fenobam to reduce the hypersensitivity caused by the heat/capsaicin 
experimental hyperalgesia model in healthy human volunteers. The heat/capsaicin model 
is a safe and non-invasive method that utilizes serial application of heat and capsaicin to 
synergistically  produce stable, long-lasting, and reproducible hyperalgesia and 
hypersensitivity  in human subjects (Dirks, 2003). The application of both heat and 
capsaicin produces an expanded area of hypersensitivity and allodynia outside of the area 
of application that is akin to that caused by  central sensitization following frank tissue 
injury. Multiple studies have illustrated that drugs with known analgesic efficacy, 
including gabapentin (Dirks, 2002) and morphine (Frymoyer, 2007), reduce the 
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hypersensitivity  induced by  the heat/capsaicin model. To test directly whether antagonism 
of mGlu5 can reduce central sensitization in human subjects it would be possible to 
induce sensitization using the heat/capsaicin model and compare the ability  of fenobam to 
reverse this sensitization relative to placebo in a double-blind crossover study. 
Performing this study would provide direct evidence of the efficacy of fenobam to reduce 
hypersensitivity  in a validated human experimental model of central sensitization and 
may provide the rationale for continued development of mGlu5 antagonists as analgesics 
in humans.
 The heat/capsaicin hyperalgesia model combines serial heat stimulation (45º C for 5 
min) applied to a 15.7 cm2 area of skin on the forearm and topical low dose capsaicin 
(0.1% Capzacin-HP Cream; Chattem, Chattanooga, TN) applied to the same area. This 
combination produces reversible pain and the sensory changes associated with peripheral 
and central sensitization for up to 4 hours. Application of thermal stimulations are applied 
in a precise and controlled manner using a Medoc Advanced Thermal Stimulator (Medoc, 
Ramat Yishai, Israel) driving a 9 cm2 thermode. The thermode is a computer-controlled 
Peltier device that warms the skin from 32º C to a safety cutoff of 50º C in 1º C / s 
increments. The heat/capsaicin model has been utilized in numerous studies involving 
human subjects that  demonstrate that it is safe and reliable and does not damage skin 
(Abrams et al., 2007; Dirks et al., 2001, 2002, 2003).
 The following methods would be used to induce and quantify pain and central 
sensitization: A) pain intensity produced by 45º C thermal stimulation for 1 minute, B) 
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heat pain detection threshold to a 1º C ramp stimulus from 32º C to 50º C, C) the pain 
intensity and area (in cm2) of secondary hyperalgesia and allodynia induced by  the heat/
capsaicin model.
 Central sensitization would be established by heating the volar surface of the 
dominant forearm using the thermode set to 45º C for 5 minutes, followed by immediate 
application of approximately 0.5 ounces of 0.1% capsaicin cream covering the previously 
heated surface (9 cm2). The cream would be left on for 30 minutes and then wiped off. At 
the end of the 30 minute capsaicin application, measurements would be performed to 
determine the areas of hypersensitivity and allodynia on the forearm. The borders of 
secondary  hyperalgesia would be mapped using a 1 inch foam brush and a nylon Von 
Frey filament (26 g bending force) along four linear paths between the thermode outline 
and 1) the antecubital fossa , 2) the wrist joint, 3) the lateral aspect of the forearm in 
anatomical position, and 4) the medial aspect of the forearm (Figure 1).
 Hypersensitivity would be maintained by  “rekindling” the site of heat/capsaicin 
application by  re-stimulating the previously treated skin four times at 40 minute intervals 
with the thermode set to a lower temperature (40º C) for 5 min. Rekindling has been 
shown to maintain robust and consistent hypersensitivity in human subjects for at  least 4 
hours (Dirks, 2003). 
 It would be possible to study the effects of fenobam on the hypersensitivity  caused 
by the heat/capsaicin model by calculating the change from baseline hypersensitivity due 
to the effects of fenobam and comparing it to an inert placebo. Baseline would be defined 
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Figure 1: The Heat/Capsaicin Model.
A) Photograph of a subject’s forearm immediately following the first rekindling. Note the erythema 
within and around the thermode outline. Marked lines indicate locations where stimulation with a foam 
brush was perceived as painful. Hash marks indicate locations where stimulation with a 26 g Von Frey 
hair was perceived as painful. Black, red, and blue marks indicate measurements performed following 
the 5 min 45º C heating, the 30 minute capsaicin application, and the first rekindling (5 min at 40º C) 
respectively. B) Use of the foam brush to map out the area of hypersensitivity following capsaicin cream 
application. C) Diagram demonstrating how the area of hypersensitivity from 4 hypothetical Von Frey 
measurements (X marks) would be calculated.
as the size of the area of hypersensitivity immediately following the first  rekindling. After 
the first rekindling either fenobam (150 mg per os) or placebo would be administered. 
Three post-drug rekindling sessions would then be performed. After the third post-drug 
rekindling procedure the area of the hypersensitivity  would be mapped and any change 
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from baseline hypersensitivity would be determined. In addition, it  would be possible to 
quantify the fenobam plasma concentration by performing a blood draw on the volunteers 
and then performing liquid chromatography-mass spectrometry on the plasma as 
described in Chapter 3. Finally, assessment for tolerability and safety following fenobam 
administration would be readily comparable to inert placebo. 
 Based on previously published findings assessing the effects of orally  administered 
fenobam in healthy  volunteers (Berry-Kravis, 2009), it is expected that fenobam at  doses 
up to 150 mg will be well tolerated with minimal side effects. It is also anticipated that 
fenobam administration will reduce the heat/capsaicin-induced area of hypersensitivity 
on the forearm, as compared to placebo. Fenobam is also expected to reduce the pain 
intensity during rekindling when compared to placebo. These findings would indicate that 
fenobam is capable of reducing central sensitization and suggest a prominent role for 
mGlu5 in the maintenance of central sensitization in human subjects. It would also 
encourage the testing of the analgesic efficacy of fenobam in human pain patients.
 In conclusion the work in this thesis supports the development of mGlu5 
antagonists as analgesics, provided that care is taken in the assessment for clinically 
significant deleterious effects.
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